{"data": [{"referenced_tweets": [{"type": "retweeted", "id": "1600947865161199616"}], "id": "1601016176108523520", "entities": {"hashtags": [{"start": 45, "end": 51, "tag": "ASH22"}], "mentions": [{"start": 3, "end": 17, "username": "CyclingDoctor", "id": "23036480"}, {"start": 67, "end": 76, "username": "WUSTLmed", "id": "27779882"}, {"start": 101, "end": 117, "username": "WUHemeOncFellow", "id": "1541500129399775234"}, {"start": 120, "end": 135, "username": "SanaSaifUrRehm", "id": "1533874462503972865"}]}, "text": "RT @CyclingDoctor: Check out some of the \ud835\udfed\ud835\udff1\ud835\udfee #ASH22 abstracts from @WUSTLmed including many from our @WUHemeOncFellow \n\n@SanaSaifUrRehm @Mi\u2026", "lang": "en", "author_id": "626650397", "conversation_id": "1601016176108523520", "edit_history_tweet_ids": ["1601016176108523520"], "created_at": "2022-12-09T00:49:36.000Z"}, {"referenced_tweets": [{"type": "replied_to", "id": "1600594512774311937"}], "id": "1600685641809162240", "text": "@dgermain21 @TheWonkologist Can confirm (and it\u2019s brought a great dimension to our discussions of cost at conference)", "lang": "en", "author_id": "626650397", "conversation_id": "1600574596566106156", "edit_history_tweet_ids": ["1600685641809162240"], "created_at": "2022-12-08T02:56:10.000Z", "entities": {"mentions": [{"start": 0, "end": 11, "username": "dgermain21", "id": "18821994"}, {"start": 12, "end": 27, "username": "TheWonkologist", "id": "3234116877"}]}, "in_reply_to_user_id": "18821994"}, {"entities": {"annotations": [{"start": 64, "end": 69, "probability": 0.8384, "type": "Organization", "normalized_text": "google"}], "mentions": [{"start": 0, "end": 8, "username": "mtmdphd", "id": "190337035"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1600675917986115584"}], "id": "1600679562098409473", "text": "@mtmdphd \u2026this has been haunting me and is surprisingly hard to google. One looped closed \ud83d\udc4d", "lang": "en", "author_id": "626650397", "conversation_id": "1600642889280798721", "edit_history_tweet_ids": ["1600679562098409473"], "created_at": "2022-12-08T02:32:01.000Z", "in_reply_to_user_id": "626650397"}, {"referenced_tweets": [{"type": "replied_to", "id": "1600673744728489984"}], "id": "1600676866431541248", "text": "@VincentRK @CyclingDoctor @LabFehniger @DiPersioLab @AaronGoodman33 @ManniMD1 @DavidSteensma @bdermanmd @VPrasadMDMPH @myelomaMD @Geoff_Uy I love the idea of printing a stack and having a tactile pile to work through. Definitely better than the 12 browser tabs I have open.", "lang": "en", "author_id": "626650397", "conversation_id": "1600642889280798721", "edit_history_tweet_ids": ["1600676866431541248"], "created_at": "2022-12-08T02:21:18.000Z", "entities": {"mentions": [{"start": 0, "end": 10, "username": "VincentRK", "id": "24261916"}, {"start": 11, "end": 25, "username": "CyclingDoctor", "id": "23036480"}, {"start": 26, "end": 38, "username": "LabFehniger", "id": "1198731683199098881"}, {"start": 39, "end": 51, "username": "DiPersioLab", "id": "1349142172415762433"}, {"start": 52, "end": 67, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 68, "end": 77, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 78, "end": 92, "username": "DavidSteensma", "id": "2739065578"}, {"start": 93, "end": 103, "username": "bdermanmd", "id": "872983600416862208"}, {"start": 104, "end": 117, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 118, "end": 128, "username": "myelomaMD", "id": "301568235"}, {"start": 129, "end": 138, "username": "Geoff_Uy", "id": "985139345928736768"}]}, "in_reply_to_user_id": "24261916"}, {"entities": {"annotations": [{"start": 224, "end": 230, "probability": 0.6219, "type": "Other", "normalized_text": "Twitter"}], "hashtags": [{"start": 191, "end": 196, "tag": "mmsm"}], "mentions": [{"start": 0, "end": 10, "username": "judalebow", "id": "3025849894"}, {"start": 11, "end": 25, "username": "CyclingDoctor", "id": "23036480"}, {"start": 26, "end": 38, "username": "LabFehniger", "id": "1198731683199098881"}, {"start": 39, "end": 51, "username": "DiPersioLab", "id": "1349142172415762433"}, {"start": 52, "end": 67, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 68, "end": 77, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 78, "end": 92, "username": "DavidSteensma", "id": "2739065578"}, {"start": 93, "end": 103, "username": "bdermanmd", "id": "872983600416862208"}, {"start": 104, "end": 117, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 118, "end": 128, "username": "VincentRK", "id": "24261916"}, {"start": 129, "end": 139, "username": "myelomaMD", "id": "301568235"}, {"start": 140, "end": 149, "username": "Geoff_Uy", "id": "985139345928736768"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1600669885931040768"}], "id": "1600676439942393856", "text": "@judalebow @CyclingDoctor @LabFehniger @DiPersioLab @AaronGoodman33 @ManniMD1 @DavidSteensma @bdermanmd @VPrasadMDMPH @VincentRK @myelomaMD @Geoff_Uy Thanks for the advice! Following all the #mmsm experts why I\u2019ve stayed on Twitter despite the inevitable time suck \ud83d\ude02", "lang": "en", "author_id": "626650397", "conversation_id": "1600642889280798721", "edit_history_tweet_ids": ["1600676439942393856"], "created_at": "2022-12-08T02:19:37.000Z", "in_reply_to_user_id": "3025849894"}, {"referenced_tweets": [{"type": "replied_to", "id": "1600659677607591936"}], "id": "1600675917986115584", "text": "@mtmdphd This is great! Dumb question: as a tech illiterate\u2026 what does the \u201csm\u201d in all these hashtags stand for?", "lang": "en", "author_id": "626650397", "conversation_id": "1600642889280798721", "edit_history_tweet_ids": ["1600675917986115584"], "created_at": "2022-12-08T02:17:32.000Z", "entities": {"mentions": [{"start": 0, "end": 8, "username": "mtmdphd", "id": "190337035"}]}, "in_reply_to_user_id": "190337035"}, {"referenced_tweets": [{"type": "replied_to", "id": "1600642889280798721"}], "id": "1600643211177127936", "text": "Do you search for keywords? Read the all sessions for your area of interest? Do you already know about them from other conferences or because you served as an abstract reviewer?", "lang": "en", "author_id": "626650397", "conversation_id": "1600642889280798721", "edit_history_tweet_ids": ["1600643211177127936"], "created_at": "2022-12-08T00:07:34.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 63, "end": 69, "probability": 0.6243, "type": "Other", "normalized_text": "ASH2022"}], "hashtags": [{"start": 62, "end": 70, "tag": "ASH2022"}], "mentions": [{"start": 141, "end": 155, "username": "CyclingDoctor", "id": "23036480"}, {"start": 156, "end": 168, "username": "LabFehniger", "id": "1198731683199098881"}, {"start": 169, "end": 181, "username": "DiPersioLab", "id": "1349142172415762433"}, {"start": 182, "end": 197, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 198, "end": 207, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 208, "end": 222, "username": "DavidSteensma", "id": "2739065578"}, {"start": 223, "end": 233, "username": "bdermanmd", "id": "872983600416862208"}, {"start": 234, "end": 247, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 248, "end": 258, "username": "VincentRK", "id": "24261916"}, {"start": 259, "end": 269, "username": "myelomaMD", "id": "301568235"}, {"start": 270, "end": 279, "username": "Geoff_Uy", "id": "985139345928736768"}]}, "id": "1600642889280798721", "text": "As a trainee who\u2019s overwhelmed by the volume of abstracts for #ASH2022, any advice on filtering/reviewing/scheduling from the senior folks?\n\n@CyclingDoctor @LabFehniger @DiPersioLab @AaronGoodman33 @ManniMD1 @DavidSteensma @bdermanmd @VPrasadMDMPH @VincentRK @myelomaMD @Geoff_Uy", "lang": "en", "author_id": "626650397", "conversation_id": "1600642889280798721", "edit_history_tweet_ids": ["1600642889280798721"], "created_at": "2022-12-08T00:06:17.000Z"}, {"entities": {"annotations": [{"start": 152, "end": 154, "probability": 0.5042, "type": "Place", "normalized_text": "StL"}], "mentions": [{"start": 0, "end": 16, "username": "LouisWilliamsMD", "id": "1283867959979630596"}, {"start": 17, "end": 33, "username": "RahulBanerjeeMD", "id": "26399236"}, {"start": 34, "end": 41, "username": "INizMD", "id": "1126278189549072385"}, {"start": 42, "end": 56, "username": "DavidSteensma", "id": "2739065578"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1598645056436547585"}], "id": "1598718636293865475", "text": "@LouisWilliamsMD @RahulBanerjeeMD @INizMD @DavidSteensma I will forever rep the midsized Midwest metro QoL, especially on a trainee salary (shoutout to StL). It\u2019d be hard to give up the house we bought in residency for a 1 bedroom apartment rental at a higher price point. People may just pick their lifestyle lanes by  fellowship.", "lang": "en", "author_id": "626650397", "conversation_id": "1598480153872666624", "edit_history_tweet_ids": ["1598718636293865475"], "created_at": "2022-12-02T16:40:00.000Z", "in_reply_to_user_id": "1283867959979630596"}, {"entities": {"annotations": [{"start": 199, "end": 204, "probability": 0.9563, "type": "Place", "normalized_text": "Boston"}], "mentions": [{"start": 0, "end": 16, "username": "RahulBanerjeeMD", "id": "26399236"}, {"start": 17, "end": 24, "username": "INizMD", "id": "1126278189549072385"}, {"start": 25, "end": 39, "username": "DavidSteensma", "id": "2739065578"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1598515663509028865"}], "id": "1598535745995788290", "text": "@RahulBanerjeeMD @INizMD @DavidSteensma I interviewed with them in 2019 and they were still naming it and working on it. I think it\u2019s a hard sell for a lot of folks (myself included) to re-locate to Boston in their 30s. It\u2019s fun but horribly expensive and rather cold.", "lang": "en", "author_id": "626650397", "conversation_id": "1598480153872666624", "edit_history_tweet_ids": ["1598535745995788290"], "created_at": "2022-12-02T04:33:15.000Z", "in_reply_to_user_id": "26399236"}, {"referenced_tweets": [{"type": "replied_to", "id": "1598493681853546497"}], "id": "1598533717152206861", "text": "@dgermain21 @JineshGheeya What\u2019s the failure point that leads stuff like this getting into print? Obviously, someone wrote it and the authors signed off on it. But should the editors/reviewers allow it?", "lang": "en", "author_id": "626650397", "conversation_id": "1598458399670280194", "edit_history_tweet_ids": ["1598533717152206861"], "created_at": "2022-12-02T04:25:12.000Z", "entities": {"mentions": [{"start": 0, "end": 11, "username": "dgermain21", "id": "18821994"}, {"start": 12, "end": 25, "username": "JineshGheeya", "id": "1561772329138626560"}]}, "in_reply_to_user_id": "18821994"}, {"entities": {"annotations": [{"start": 66, "end": 75, "probability": 0.5878, "type": "Other", "normalized_text": "Belantamab"}], "mentions": [{"start": 0, "end": 10, "username": "VincentRK", "id": "24261916"}, {"start": 11, "end": 20, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 21, "end": 27, "username": "GSKUS", "id": "22623663"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1595451503623430146"}], "id": "1595452142202101760", "text": "@VincentRK @ManniMD1 @GSKUS Thanks for this thread, by the way. \n\nBelantamab getting pulled is a very complicated clinical/regulatory event and getting a perspective from someone with this depth of experience in the field is invaluable.", "lang": "en", "author_id": "626650397", "conversation_id": "1595220125631881217", "edit_history_tweet_ids": ["1595452142202101760"], "created_at": "2022-11-23T16:20:07.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 140, "end": 142, "probability": 0.4484, "type": "Other", "normalized_text": "TCR"}, {"start": 147, "end": 149, "probability": 0.3929, "type": "Other", "normalized_text": "PCR"}, {"start": 177, "end": 186, "probability": 0.4507, "type": "Other", "normalized_text": "belantamab"}, {"start": 227, "end": 230, "probability": 0.3853, "type": "Other", "normalized_text": "HDCy"}, {"start": 235, "end": 238, "probability": 0.4408, "type": "Other", "normalized_text": "DCEP"}], "mentions": [{"start": 0, "end": 10, "username": "VincentRK", "id": "24261916"}, {"start": 11, "end": 20, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 21, "end": 27, "username": "GSKUS", "id": "22623663"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1595228631835500545"}], "id": "1595451503623430146", "text": "@VincentRK @ManniMD1 @GSKUS If the goal is to get agents that work when we're running out of options, would the right approach be to enroll TCR or PCR patients for single agent belantamab vs. physician's choice therapy? (Often HDCy or DCEP at our center).", "lang": "en", "author_id": "626650397", "conversation_id": "1595220125631881217", "edit_history_tweet_ids": ["1595451503623430146"], "created_at": "2022-11-23T16:17:35.000Z", "in_reply_to_user_id": "24261916"}, {"referenced_tweets": [{"type": "quoted", "id": "1595425108964900867"}], "id": "1595448834817417216", "entities": {"urls": [{"start": 186, "end": 209, "url": "https://t.co/luXqBx2IDm", "expanded_url": "https://twitter.com/DavidSteensma/status/1595425108964900867", "display_url": "twitter.com/DavidSteensma/\u2026"}]}, "text": "I genuinely love \"back in my day\" stories from senior physicians. For those of us just setting our feet to the path, it's a reminder to dream big and work to make ourselves unnecessary. https://t.co/luXqBx2IDm", "lang": "en", "author_id": "626650397", "conversation_id": "1595448834817417216", "edit_history_tweet_ids": ["1595448834817417216"], "created_at": "2022-11-23T16:06:58.000Z"}, {"entities": {"annotations": [{"start": 76, "end": 78, "probability": 0.4686, "type": "Other", "normalized_text": "GSK"}, {"start": 123, "end": 131, "probability": 0.597, "type": "Other", "normalized_text": "BCMA BSAb"}], "mentions": [{"start": 0, "end": 13, "username": "Abdallah81MD", "id": "1026947037080772610"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1595193541982134273"}], "id": "1595230778471976961", "text": "@Abdallah81MD I feel like this was the biggest one... smart people work for GSK and they read the tea leaves. Once an anti-BCMA BSAb is widely available, who wants to deal with the (potentially life altering) ocular toxicity for half the efficacy?", "lang": "en", "author_id": "626650397", "conversation_id": "1595193537674575872", "edit_history_tweet_ids": ["1595230778471976961"], "created_at": "2022-11-23T01:40:30.000Z", "in_reply_to_user_id": "1026947037080772610"}, {"referenced_tweets": [{"type": "quoted", "id": "1594715525963485184"}], "id": "1594729734206029825", "entities": {"urls": [{"start": 26, "end": 49, "url": "https://t.co/WZAc3baxna", "expanded_url": "https://twitter.com/RahulBanerjeeMD/status/1594715525963485184", "display_url": "twitter.com/RahulBanerjeeM\u2026"}]}, "text": "This. Both parts of this. https://t.co/WZAc3baxna", "lang": "en", "author_id": "626650397", "conversation_id": "1594729734206029825", "edit_history_tweet_ids": ["1594729734206029825"], "created_at": "2022-11-21T16:29:31.000Z"}, {"entities": {"annotations": [{"start": 4, "end": 7, "probability": 0.6154, "type": "Other", "normalized_text": "Kreb"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1594474451252412419"}], "id": "1594474452737085440", "text": "The Kreb's cycle. Not again. Not ever.", "lang": "en", "author_id": "626650397", "conversation_id": "1594474444805767169", "edit_history_tweet_ids": ["1594474452737085440"], "created_at": "2022-11-20T23:35:08.000Z", "in_reply_to_user_id": "626650397"}, {"referenced_tweets": [{"type": "replied_to", "id": "1594474449897668610"}], "id": "1594474451252412419", "text": "Starting doses of oral small molecules (unless compared meaningfully in a clinical trial)", "lang": "en", "author_id": "626650397", "conversation_id": "1594474444805767169", "edit_history_tweet_ids": ["1594474451252412419"], "created_at": "2022-11-20T23:35:07.000Z", "in_reply_to_user_id": "626650397"}, {"referenced_tweets": [{"type": "replied_to", "id": "1594474448350244864"}], "id": "1594474449897668610", "text": "Response rates from trials that are of \"historical interest\"", "lang": "en", "author_id": "626650397", "conversation_id": "1594474444805767169", "edit_history_tweet_ids": ["1594474449897668610"], "created_at": "2022-11-20T23:35:07.000Z", "in_reply_to_user_id": "626650397"}, {"referenced_tweets": [{"type": "replied_to", "id": "1594474446655717376"}], "id": "1594474448350244864", "text": "Any syndrome defined by a triad", "lang": "en", "author_id": "626650397", "conversation_id": "1594474444805767169", "edit_history_tweet_ids": ["1594474448350244864"], "created_at": "2022-11-20T23:35:07.000Z", "in_reply_to_user_id": "626650397"}, {"referenced_tweets": [{"type": "replied_to", "id": "1594474444805767169"}], "id": "1594474446655717376", "text": "Radiation dosing", "lang": "en", "author_id": "626650397", "conversation_id": "1594474444805767169", "edit_history_tweet_ids": ["1594474446655717376"], "created_at": "2022-11-20T23:35:06.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 37, "end": 50, "probability": 0.7665, "type": "Other", "normalized_text": "OncologyBoards"}], "hashtags": [{"start": 36, "end": 51, "tag": "OncologyBoards"}]}, "id": "1594474444805767169", "text": "Things I'm refusing to memorize for #OncologyBoards: a (running) list", "lang": "en", "author_id": "626650397", "conversation_id": "1594474444805767169", "edit_history_tweet_ids": ["1594474444805767169"], "created_at": "2022-11-20T23:35:06.000Z"}, {"id": "1594028518584770560", "entities": {"urls": [{"start": 182, "end": 205, "url": "https://t.co/oMqKOaagqc", "expanded_url": "https://twitter.com/MichaelJSlade/status/1594028518584770560/photo/1", "display_url": "pic.twitter.com/oMqKOaagqc", "media_key": "3_1594028342675742720"}], "mentions": [{"start": 168, "end": 180, "username": "NTrikalinos", "id": "1242826524010651653"}]}, "text": "When you need to take an oncology boards study break from \"high yield\" topics and review something that's not terribly testable but is terribly interesting \n\n(shout to @NTrikalinos) https://t.co/oMqKOaagqc", "lang": "en", "author_id": "626650397", "conversation_id": "1594028518584770560", "edit_history_tweet_ids": ["1594028518584770560"], "created_at": "2022-11-19T18:03:09.000Z"}, {"entities": {"annotations": [{"start": 133, "end": 136, "probability": 0.6864, "type": "Other", "normalized_text": "ADCs"}, {"start": 142, "end": 158, "probability": 0.8861, "type": "Other", "normalized_text": "urothelial cancer"}], "mentions": [{"start": 0, "end": 16, "username": "RahulBanerjeeMD", "id": "26399236"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1592990088082100224"}], "id": "1593018307216826372", "text": "@RahulBanerjeeMD Plus there\u2019s category 1 data for second line for certain patients. Very testable and more relevant than fourth line ADCs for urothelial cancer or targeted therapies for &lt;1% of some rare solid tumor (he says with obvious bias).", "lang": "en", "author_id": "626650397", "conversation_id": "1592942968209408000", "edit_history_tweet_ids": ["1593018307216826372"], "created_at": "2022-11-16T23:08:55.000Z", "in_reply_to_user_id": "26399236"}, {"entities": {"annotations": [{"start": 181, "end": 194, "probability": 0.7632, "type": "Other", "normalized_text": "myeloma clinic"}], "mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 10, "end": 18, "username": "iStopMM", "id": "844232399319941122"}, {"start": 19, "end": 33, "username": "sykristinsson", "id": "3078258341"}, {"start": 81, "end": 89, "username": "iStopMM", "id": "844232399319941122"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1592885241953554432"}], "id": "1592949339252740099", "text": "@ManniMD1 @iStopMM @sykristinsson The sheer volume of amazing data coming out of @iStopMM has been incredible. I feel like this specific question comes up a couple times a month in myeloma clinic.", "lang": "en", "author_id": "626650397", "conversation_id": "1592885241953554432", "edit_history_tweet_ids": ["1592949339252740099"], "created_at": "2022-11-16T18:34:52.000Z", "in_reply_to_user_id": "1269642863924609025"}, {"entities": {"annotations": [{"start": 142, "end": 147, "probability": 0.5813, "type": "Other", "normalized_text": "cancer"}, {"start": 197, "end": 201, "probability": 0.2962, "type": "Other", "normalized_text": "McRib"}], "mentions": [{"start": 0, "end": 14, "username": "NicoGagelmann", "id": "1054759355512438786"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1592793042528120835"}], "id": "1592945462994427907", "text": "@NicoGagelmann I have been surprised how many patients/families I've seen in clinic ask if there's a diet they can follow to help treat their cancer. \n\nIt's all about joy. I literally prescribed a McRib last week in a patient with an advanced cancer.", "lang": "en", "author_id": "626650397", "conversation_id": "1592793042528120835", "edit_history_tweet_ids": ["1592945462994427907"], "created_at": "2022-11-16T18:19:28.000Z", "in_reply_to_user_id": "1054759355512438786"}, {"entities": {"annotations": [{"start": 38, "end": 52, "probability": 0.5214, "type": "Other", "normalized_text": "Oncology Boards"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1592942968209408000"}], "id": "1592943149013700608", "text": "On the plus side, nobody studying for Oncology Boards is obligated to memorize co-stimulatory domains.", "lang": "en", "author_id": "626650397", "conversation_id": "1592942968209408000", "edit_history_tweet_ids": ["1592943149013700608"], "created_at": "2022-11-16T18:10:16.000Z", "in_reply_to_user_id": "626650397"}, {"id": "1592942968209408000", "entities": {"urls": [{"start": 24, "end": 47, "url": "https://t.co/FjT0MK4Xuv", "expanded_url": "https://twitter.com/MichaelJSlade/status/1592942968209408000/photo/1", "display_url": "pic.twitter.com/FjT0MK4Xuv", "media_key": "3_1592942525232431105"}]}, "text": "Well, this is crushing: https://t.co/FjT0MK4Xuv", "lang": "en", "author_id": "626650397", "conversation_id": "1592942968209408000", "edit_history_tweet_ids": ["1592942968209408000"], "created_at": "2022-11-16T18:09:33.000Z"}, {"referenced_tweets": [{"type": "retweeted", "id": "1587997743255093250"}], "id": "1588376931808182272", "text": "RT @Garth_Nicholas1: Over time I\u2019ve tweeted a lot about evidence-based medicine. But oncologists are often in situations with little or no\u2026", "lang": "en", "author_id": "626650397", "conversation_id": "1588376931808182272", "edit_history_tweet_ids": ["1588376931808182272"], "created_at": "2022-11-04T03:45:45.000Z", "entities": {"mentions": [{"start": 3, "end": 19, "username": "Garth_Nicholas1", "id": "1160789125"}]}}, {"entities": {"annotations": [{"start": 151, "end": 155, "probability": 0.5638, "type": "Other", "normalized_text": "CAR T"}], "mentions": [{"start": 0, "end": 14, "username": "CyclingDoctor", "id": "23036480"}, {"start": 15, "end": 27, "username": "DiPersioLab", "id": "1349142172415762433"}, {"start": 28, "end": 41, "username": "KellyLBolton", "id": "1108468287036407808"}, {"start": 42, "end": 53, "username": "dgermain21", "id": "18821994"}, {"start": 54, "end": 61, "username": "mpndoc", "id": "2930528191"}, {"start": 62, "end": 74, "username": "LabFehniger", "id": "1198731683199098881"}, {"start": 75, "end": 83, "username": "koetjen", "id": "31625079"}, {"start": 283, "end": 294, "username": "challenlab", "id": "906961052365197312"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1587220437242724352"}], "id": "1587226615041462273", "text": "@CyclingDoctor @DiPersioLab @KellyLBolton @dgermain21 @mpndoc @LabFehniger @koetjen Interesting! We know that detecting some CHIP-related mutations in CAR T cell products improves response depth but not duration (if memory serves). Could be a similar mechanism.  @NathanSinghLab1 or @challenlab might be able to explain this.", "lang": "en", "author_id": "626650397", "conversation_id": "1587220437242724352", "edit_history_tweet_ids": ["1587226615041462273"], "created_at": "2022-10-31T23:34:48.000Z", "in_reply_to_user_id": "23036480"}, {"entities": {"annotations": [{"start": 42, "end": 47, "probability": 0.6482, "type": "Other", "normalized_text": "cancer"}, {"start": 182, "end": 189, "probability": 0.9911, "type": "Place", "normalized_text": "New York"}], "urls": [{"start": 231, "end": 254, "url": "https://t.co/oSPcjo8Yxa", "expanded_url": "https://tinyurl.com/ypavht7r", "display_url": "tinyurl.com/ypavht7r", "images": [{"url": "https://pbs.twimg.com/news_img/1587196126909939717/B8ZsEsPq?format=jpg&name=orig", "width": 1328, "height": 801}, {"url": "https://pbs.twimg.com/news_img/1587196126909939717/B8ZsEsPq?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Food to Overcome Outcomes Disparities: A Randomized Controlled Trial of Food Insecurity Interventions to Improve Cancer Outcomes", "description": "PURPOSE Food insecurity is prevalent among low-income immigrant and minority patients with cancer. To our knowledge, this randomized controlled trial is the first to prospectively examine the impact on cancer outcomes of food insecurity interventions, with the goal of informing evidence-based interventions to address food insecurity in patients with cancer. METHODS A three-arm randomized controlled trial was conducted among food-insecure (18-item US Department of Agriculture Household Food Security Survey Module score \u2265 3) patients with cancer (N = 117) at four New York City safety net cancer clinics. Arms included a hospital cancer clinic\u2013based food pantry (arm 1), food voucher plus pantry (arm 2), and home grocery delivery plus pantry (arm 3). Treatment completion (primary outcome) and full appointment attendance were assessed at 6 months. Food security status, depression symptoms (Patient Health Questionnaire-9), and quality-of-life scores (Functional Assessment of Cancer Therapy-Ge", "unwound_url": "https://ascopubs.org/doi/full/10.1200/JCO.21.02400?bid=213501761&md5=298ec9d50999d407ceedda852c90b362&cid=DM11834"}]}, "id": "1587196122606485504", "text": "We spend an incredible amount of money in cancer care on fancy stuff and often ignore how (significantly cheaper) human stuff can improve care and outcomes. \n\nVery cool study out of New York. I hope we start seeing more like it. \n\nhttps://t.co/oSPcjo8Yxa", "lang": "en", "author_id": "626650397", "conversation_id": "1587196122606485504", "edit_history_tweet_ids": ["1587196122606485504"], "created_at": "2022-10-31T21:33:38.000Z"}, {"referenced_tweets": [{"type": "replied_to", "id": "1586726824943693824"}], "id": "1586732543767973890", "text": "@RahulBanerjeeMD @amarkelkar @Eddie_Cliff @HadidiSamer @JCO_ASCO We always talk about improved supportive care as a reason for why historical controls are misleading. This makes me wonder if international cohorts often have similar problems. \n\nProps to the authors for publishing the detailed data. Very helpful.", "lang": "en", "author_id": "626650397", "conversation_id": "1586690053060890625", "edit_history_tweet_ids": ["1586732543767973890"], "created_at": "2022-10-30T14:51:33.000Z", "entities": {"mentions": [{"start": 0, "end": 16, "username": "RahulBanerjeeMD", "id": "26399236"}, {"start": 17, "end": 28, "username": "amarkelkar", "id": "16273048"}, {"start": 29, "end": 41, "username": "Eddie_Cliff", "id": "74081884"}, {"start": 42, "end": 54, "username": "HadidiSamer", "id": "774267564"}, {"start": 55, "end": 64, "username": "JCO_ASCO", "id": "2395900849"}]}, "in_reply_to_user_id": "26399236"}, {"entities": {"annotations": [{"start": 55, "end": 58, "probability": 0.6194, "type": "Other", "normalized_text": "RCTs"}, {"start": 63, "end": 65, "probability": 0.5986, "type": "Other", "normalized_text": "HCT"}, {"start": 207, "end": 209, "probability": 0.5334, "type": "Other", "normalized_text": "HCT"}, {"start": 227, "end": 229, "probability": 0.4174, "type": "Other", "normalized_text": "HCT"}], "mentions": [{"start": 0, "end": 13, "username": "GomezDLeonMD", "id": "1039939970415218688"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1586701066145505283"}], "id": "1586728914021400578", "text": "@GomezDLeonMD This study is spectacular (so hard to do RCTs on HCT). I\u2019d love to see more data on salvage transplant in the control arm. Specifically, how many of the long term responders in the control for HCT? If no cure w/o HCT, why wait?", "lang": "en", "author_id": "626650397", "conversation_id": "1586697394732892160", "edit_history_tweet_ids": ["1586728914021400578"], "created_at": "2022-10-30T14:37:07.000Z", "in_reply_to_user_id": "1039939970415218688"}, {"referenced_tweets": [{"type": "replied_to", "id": "1586491319035531264"}], "id": "1586506131429593088", "text": "@smarmyEOD @simonbchen I\u2019m intrigued. Any good references? Any thoughts on unmeasured cofounders? Measurement error of gun-related mortality seems less likely.", "lang": "en", "author_id": "626650397", "conversation_id": "1586406414293106690", "edit_history_tweet_ids": ["1586506131429593088"], "created_at": "2022-10-29T23:51:52.000Z", "entities": {"mentions": [{"start": 0, "end": 10, "username": "smarmyEOD", "id": "3206254672"}, {"start": 11, "end": 22, "username": "simonbchen", "id": "919588789827203072"}]}, "in_reply_to_user_id": "3206254672"}, {"referenced_tweets": [{"type": "replied_to", "id": "1586451025434927104"}], "id": "1586451422660694016", "text": "@simonbchen I say this as someone who has enjoyed shooting guns since I was a pre-teen, but has no desire to own one.", "lang": "en", "author_id": "626650397", "conversation_id": "1586406414293106690", "edit_history_tweet_ids": ["1586451422660694016"], "created_at": "2022-10-29T20:14:28.000Z", "entities": {"mentions": [{"start": 0, "end": 11, "username": "simonbchen", "id": "919588789827203072"}]}, "in_reply_to_user_id": "626650397"}, {"referenced_tweets": [{"type": "replied_to", "id": "1586406414293106690"}], "id": "1586451025434927104", "text": "@simonbchen I think a lot of folks on the left are familiar with the data showing that households with guns are much, much more likely to have a firearm fatality in a member of the household than defend against an external attack. Political violence is another issue, admittedly.", "lang": "en", "author_id": "626650397", "conversation_id": "1586406414293106690", "edit_history_tweet_ids": ["1586451025434927104"], "created_at": "2022-10-29T20:12:53.000Z", "entities": {"mentions": [{"start": 0, "end": 11, "username": "simonbchen", "id": "919588789827203072"}]}, "in_reply_to_user_id": "919588789827203072"}, {"entities": {"annotations": [{"start": 180, "end": 182, "probability": 0.5146, "type": "Organization", "normalized_text": "TKI"}], "mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 32, "username": "NicholasShortMD", "id": "826584913214316546"}, {"start": 33, "end": 43, "username": "jayastuMD", "id": "1974184626"}, {"start": 44, "end": 56, "username": "LeukemiaJnl", "id": "398801458"}, {"start": 57, "end": 71, "username": "DrHKantarjian", "id": "897448268740923392"}, {"start": 72, "end": 87, "username": "MDAndersonNews", "id": "14062554"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1586430284441870336"}], "id": "1586431377645469697", "text": "@AaronGoodman33 @NicholasShortMD @jayastuMD @LeukemiaJnl @DrHKantarjian @MDAndersonNews What drives that decision? Fitness/donor availability? Depth of response to next generation TKI?", "lang": "en", "author_id": "626650397", "conversation_id": "1586397748924157952", "edit_history_tweet_ids": ["1586431377645469697"], "created_at": "2022-10-29T18:54:49.000Z", "in_reply_to_user_id": "854692626015993857"}, {"referenced_tweets": [{"type": "replied_to", "id": "1586397748924157952"}], "id": "1586428896580206592", "text": "@NicholasShortMD @jayastuMD @LeukemiaJnl @DrHKantarjian @MDAndersonNews Love it! Accelerated phase is challenging topic. Great to see a clear, concise review.", "lang": "en", "author_id": "626650397", "conversation_id": "1586397748924157952", "edit_history_tweet_ids": ["1586428896580206592"], "created_at": "2022-10-29T18:44:58.000Z", "entities": {"mentions": [{"start": 0, "end": 16, "username": "NicholasShortMD", "id": "826584913214316546"}, {"start": 17, "end": 27, "username": "jayastuMD", "id": "1974184626"}, {"start": 28, "end": 40, "username": "LeukemiaJnl", "id": "398801458"}, {"start": 41, "end": 55, "username": "DrHKantarjian", "id": "897448268740923392"}, {"start": 56, "end": 71, "username": "MDAndersonNews", "id": "14062554"}]}, "in_reply_to_user_id": "826584913214316546"}, {"entities": {"annotations": [{"start": 156, "end": 158, "probability": 0.4987, "type": "Other", "normalized_text": "TTP"}, {"start": 176, "end": 178, "probability": 0.5291, "type": "Other", "normalized_text": "CLL"}, {"start": 180, "end": 182, "probability": 0.3259, "type": "Other", "normalized_text": "OSH"}, {"start": 220, "end": 222, "probability": 0.4065, "type": "Organization", "normalized_text": "AML"}], "mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1586403917365010432"}], "id": "1586427963909677056", "text": "@AaronGoodman33 Love it. I would add: folks often don't know what they don't know. If you fight someone for critical illness TCP, they may not call you for TTP. If you block a CLL OSH transfer, they may not call you for AML. \n\nBe nice. Be educational. It's good for patients.", "lang": "en", "author_id": "626650397", "conversation_id": "1586403917365010432", "edit_history_tweet_ids": ["1586427963909677056"], "created_at": "2022-10-29T18:41:15.000Z", "in_reply_to_user_id": "854692626015993857"}, {"entities": {"annotations": [{"start": 8, "end": 16, "probability": 0.7078, "type": "Other", "normalized_text": "BRAF V600"}, {"start": 76, "end": 85, "probability": 0.7091, "type": "Other", "normalized_text": "dabrafenib"}, {"start": 87, "end": 96, "probability": 0.6823, "type": "Other", "normalized_text": "trametinib"}, {"start": 135, "end": 138, "probability": 0.7774, "type": "Other", "normalized_text": "NTRK"}, {"start": 159, "end": 161, "probability": 0.5598, "type": "Other", "normalized_text": "RET"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1586396680882212868"}], "id": "1586396683227000832", "text": "Answer: BRAF V600 mutations (present in 10 - 50% of patients), treated with dabrafenib/trametinib. \n\nAlso tissue agnostic approval for NTRK fusion cancers and RET fusion thyroid cancers, which occur in a small subset of patients.", "lang": "en", "author_id": "626650397", "conversation_id": "1586396680882212868", "edit_history_tweet_ids": ["1586396683227000832"], "created_at": "2022-10-29T16:36:57.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 27, "end": 29, "probability": 0.9194, "type": "Organization", "normalized_text": "FDA"}, {"start": 73, "end": 86, "probability": 0.4272, "type": "Other", "normalized_text": "thyroid cancer"}]}, "id": "1586396680882212868", "text": "Board factoid #1:\n\nWe have FDA approved medical treatment for anaplastic thyroid cancer! What mutation is targeted and what agents are used?", "lang": "en", "author_id": "626650397", "conversation_id": "1586396680882212868", "edit_history_tweet_ids": ["1586396680882212868"], "created_at": "2022-10-29T16:36:57.000Z"}, {"entities": {"annotations": [{"start": 55, "end": 61, "probability": 0.9694, "type": "Other", "normalized_text": "twitter"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1586393838217633792"}], "id": "1586394167202258948", "text": "And yes, this is an excuse to stop studying and get on twitter instead. Don't shame me.", "lang": "en", "author_id": "626650397", "conversation_id": "1586393838217633792", "edit_history_tweet_ids": ["1586394167202258948"], "created_at": "2022-10-29T16:26:57.000Z", "in_reply_to_user_id": "626650397"}, {"id": "1586393838217633792", "text": "Studying for the boards is awesome. It's an opportunity to be reminded of subtleties re: agents or diseases you don't see much in your area of focus. \n\nFor the next *checks calendar* four weeks, I'll be posting boards factoids that I never knew (or forgot).\n\nGood luck studying!", "lang": "en", "author_id": "626650397", "conversation_id": "1586393838217633792", "edit_history_tweet_ids": ["1586393838217633792"], "created_at": "2022-10-29T16:25:39.000Z"}, {"entities": {"annotations": [{"start": 87, "end": 88, "probability": 0.5856, "type": "Other", "normalized_text": "MM"}], "mentions": [{"start": 0, "end": 14, "username": "CyclingDoctor", "id": "23036480"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1585937001928622080"}], "id": "1586180532328546304", "text": "@CyclingDoctor This is fascinating. Is it exacerbating a pre-existing immune defect in MM or is this a reflection of length of therapy and competing risks?", "lang": "en", "author_id": "626650397", "conversation_id": "1585937001928622080", "edit_history_tweet_ids": ["1586180532328546304"], "created_at": "2022-10-29T02:18:03.000Z", "in_reply_to_user_id": "23036480"}, {"referenced_tweets": [{"type": "replied_to", "id": "1586133213147037696"}], "id": "1586162861021200385", "text": "To clarify: From what I\u2019ve seen, the trial was methodologically sound, ethically conducted and scientifically important. I was just disappointed by the framing of the discussion.", "lang": "en", "author_id": "626650397", "conversation_id": "1586133202787135488", "edit_history_tweet_ids": ["1586162861021200385"], "created_at": "2022-10-29T01:07:50.000Z", "in_reply_to_user_id": "626650397"}, {"referenced_tweets": [{"type": "replied_to", "id": "1586133210832211969"}], "id": "1586133213147037696", "text": "Worth noting the senior author on this manuscript is an @AstellasUS  employee and paid medical writers were involved in drafting. Maybe this is why the discussion reads like a press release. \n\nOverall: good study, moves field forward, but discussion leaves bad taste.  \n\n/end", "lang": "en", "author_id": "626650397", "conversation_id": "1586133202787135488", "edit_history_tweet_ids": ["1586133213147037696"], "created_at": "2022-10-28T23:10:01.000Z", "entities": {"mentions": [{"start": 56, "end": 67, "username": "AstellasUS", "id": "27900939"}]}, "in_reply_to_user_id": "626650397"}, {"referenced_tweets": [{"type": "replied_to", "id": "1586133208621404160"}], "id": "1586133210832211969", "text": "I wish editorial control was a little tighter for study design-related fallacies. If someone misrepresents prior literature or uses the wrong statistical approach, the paper is not accepted until it's fixed. Can't we do the same here?\n\n5/n", "lang": "en", "author_id": "626650397", "conversation_id": "1586133202787135488", "edit_history_tweet_ids": ["1586133210832211969"], "created_at": "2022-10-28T23:10:01.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 114, "end": 116, "probability": 0.4567, "type": "Other", "normalized_text": "RCT"}, {"start": 205, "end": 208, "probability": 0.8045, "type": "Other", "normalized_text": "FLT3"}, {"start": 230, "end": 233, "probability": 0.6334, "type": "Other", "normalized_text": "RCTs"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1586133206822457344"}], "id": "1586133208621404160", "text": "It went on to blame (appropriate) subsequent therapy  and a (NS) imbalance in baseline demographic factors (in an RCT) for lack of OS benefit. It also noted a sicker (randomized) cohort and enrichment for FLT3 mutations vs. other RCTs in space (sigh) .  \n\n4/n", "lang": "en", "author_id": "626650397", "conversation_id": "1586133202787135488", "edit_history_tweet_ids": ["1586133208621404160"], "created_at": "2022-10-28T23:10:00.000Z", "in_reply_to_user_id": "626650397"}, {"referenced_tweets": [{"type": "replied_to", "id": "1586133204947423243"}], "id": "1586133206822457344", "text": "Second, complaints:\n\nHonestly, mostly the discussion (this will go on awhile). The first paragraph was bad. It admitted the study was negative, but went on to tout a 1 month OS diff (NS) overall, 6.3 month OS diff in high allelic ratio (NS, not power, not pre-specified).  \n\n3/n", "lang": "en", "author_id": "626650397", "conversation_id": "1586133202787135488", "edit_history_tweet_ids": ["1586133206822457344"], "created_at": "2022-10-28T23:10:00.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 18, "end": 21, "probability": 0.4346, "type": "Other", "normalized_text": "RCTs"}, {"start": 180, "end": 182, "probability": 0.8774, "type": "Place", "normalized_text": "USA"}, {"start": 246, "end": 251, "probability": 0.9501, "type": "Place", "normalized_text": "Canada"}, {"start": 253, "end": 258, "probability": 0.9539, "type": "Place", "normalized_text": "Europe"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1586133202787135488"}], "id": "1586133204947423243", "text": "First, kudos:\n\n1) RCTs are hard. Congrats to authors, despite a negative study\n2) Huge area of need. Older patients aren't studied enough. Median age 75+, ~45% ECOG 2. \n3) For non-USA pop, aza control arm = okay. Last enrolled 8/2020, pre-Ven in Canada/Europe\n4) OS endpoint!\n\n2/n", "lang": "en", "author_id": "626650397", "conversation_id": "1586133202787135488", "edit_history_tweet_ids": ["1586133204947423243"], "created_at": "2022-10-28T23:09:59.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 21, "end": 31, "probability": 0.6475, "type": "Other", "normalized_text": "azacytidine"}, {"start": 53, "end": 56, "probability": 0.6584, "type": "Other", "normalized_text": "FLT3"}, {"start": 157, "end": 159, "probability": 0.4162, "type": "Other", "normalized_text": "AML"}, {"start": 201, "end": 204, "probability": 0.8043, "type": "Other", "normalized_text": "FLT3"}], "urls": [{"start": 243, "end": 266, "url": "https://t.co/vB56Nzeoy6", "expanded_url": "https://tinyurl.com/yc35sthb", "display_url": "tinyurl.com/yc35sthb", "status": 200, "unwound_url": "https://ashpublications.org/blood/article/140/17/1845/486088/Phase-3-trial-of-gilteritinib-plus-azacitidine-vs?utm_source=&utm_medium=&utm_campaign=twib_140_17%20&utm_source=sfmc&utm_medium=email&utm_campaign=TWIB_140_17&utm_term=Link+Text+%c2%bb&utm_id=201943&sfmc_id=19361364"}], "mentions": [{"start": 103, "end": 116, "username": "BloodJournal", "id": "3407436940"}]}, "id": "1586133202787135488", "text": "The LACEWING phase 3 azacytidine +/- gilteritinib in FLT3-mut AML not eligible for intensive chemo (in @BloodJournal) shows, again, that targeted therapy in AML is hard (and targeting late events like FLT3 might not be the right approach).  \n\nhttps://t.co/vB56Nzeoy6\n\n1/n", "lang": "en", "author_id": "626650397", "conversation_id": "1586133202787135488", "edit_history_tweet_ids": ["1586133202787135488"], "created_at": "2022-10-28T23:09:59.000Z"}, {"referenced_tweets": [{"type": "replied_to", "id": "1586090748067385346"}], "id": "1586123139649372160", "text": "@dgermain21 @nancybartlettMD @LabFehniger @SitemanCenter Congrats man!", "lang": "en", "author_id": "626650397", "conversation_id": "1586090748067385346", "edit_history_tweet_ids": ["1586123139649372160"], "created_at": "2022-10-28T22:29:59.000Z", "entities": {"mentions": [{"start": 0, "end": 11, "username": "dgermain21", "id": "18821994"}, {"start": 12, "end": 28, "username": "nancybartlettMD", "id": "1172582075913986048"}, {"start": 29, "end": 41, "username": "LabFehniger", "id": "1198731683199098881"}, {"start": 42, "end": 56, "username": "SitemanCenter", "id": "89517086"}]}, "in_reply_to_user_id": "18821994"}, {"id": "1585776241189085184", "text": "Studying for oncology boards brings back all the personal cancer-related paranoia of being a first year fellow.", "lang": "en", "author_id": "626650397", "conversation_id": "1585776241189085184", "edit_history_tweet_ids": ["1585776241189085184"], "created_at": "2022-10-27T23:31:32.000Z"}, {"entities": {"annotations": [{"start": 28, "end": 37, "probability": 0.8771, "type": "Person", "normalized_text": "Paul Hinds"}, {"start": 62, "end": 78, "probability": 0.7797, "type": "Organization", "normalized_text": "United Healthcare"}, {"start": 90, "end": 94, "probability": 0.5683, "type": "Other", "normalized_text": "COBRA"}], "mentions": [{"start": 3, "end": 13, "username": "tjroycemd", "id": "1017068031166599169"}]}, "referenced_tweets": [{"type": "retweeted", "id": "1585613437400383489"}], "id": "1585754394070380545", "text": "RT @tjroycemd: The Patient: Paul Hinds, now 60, is covered by United Healthcare through a COBRA plan from his former employer.\n\nMedical Ser\u2026", "lang": "en", "author_id": "626650397", "conversation_id": "1585754394070380545", "edit_history_tweet_ids": ["1585754394070380545"], "created_at": "2022-10-27T22:04:44.000Z"}, {"entities": {"annotations": [{"start": 21, "end": 34, "probability": 0.5368, "type": "Other", "normalized_text": "WUDeptMedicine"}, {"start": 74, "end": 84, "probability": 0.5478, "type": "Other", "normalized_text": "of Oncology"}, {"start": 116, "end": 130, "probability": 0.3857, "type": "Place", "normalized_text": "Victoria Fraser"}], "hashtags": [{"start": 20, "end": 35, "tag": "WUDeptMedicine"}], "mentions": [{"start": 3, "end": 18, "username": "WUDeptMedicine", "id": "1105452868771946497"}]}, "referenced_tweets": [{"type": "retweeted", "id": "1585363441610522625"}], "id": "1585682439657111552", "text": "RT @WUDeptMedicine: #WUDeptMedicine announces new leadership for Division of Oncology. Read full announcement from  Victoria Fraser, MD, Ch\u2026", "lang": "en", "author_id": "626650397", "conversation_id": "1585682439657111552", "edit_history_tweet_ids": ["1585682439657111552"], "created_at": "2022-10-27T17:18:48.000Z"}, {"entities": {"annotations": [{"start": 113, "end": 115, "probability": 0.3718, "type": "Other", "normalized_text": "SoC"}, {"start": 175, "end": 177, "probability": 0.39, "type": "Other", "normalized_text": "SoC"}], "mentions": [{"start": 0, "end": 12, "username": "drkomanduri", "id": "1081903728"}, {"start": 13, "end": 22, "username": "szusmani", "id": "83911786"}, {"start": 23, "end": 39, "username": "SocietyofHemOnc", "id": "3300834954"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1576223837464985601"}], "id": "1576298141179031552", "text": "@drkomanduri @szusmani @SocietyofHemOnc I agree (it's a great problem to have). But we can't say both 1) current SoC is inadequate and needs improvement (yes!) and 2) current SoC is too good to beat in a RCT.  \n\nI'd love to start in high-risk patients (55.5 mo median PFS in DETERMINATION) and work from there.", "lang": "en", "author_id": "626650397", "conversation_id": "1576208128626114560", "edit_history_tweet_ids": ["1576298141179031552"], "created_at": "2022-10-01T19:48:57.000Z", "in_reply_to_user_id": "1081903728"}, {"entities": {"annotations": [{"start": 68, "end": 80, "probability": 0.568, "type": "Other", "normalized_text": "myeloma field"}, {"start": 163, "end": 163, "probability": 0.4531, "type": "Other", "normalized_text": "T"}], "mentions": [{"start": 0, "end": 12, "username": "drkomanduri", "id": "1081903728"}, {"start": 13, "end": 22, "username": "szusmani", "id": "83911786"}, {"start": 23, "end": 39, "username": "SocietyofHemOnc", "id": "3300834954"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1576208128626114560"}], "id": "1576222131653734402", "text": "@drkomanduri @szusmani @SocietyofHemOnc Love this slide. I hope the myeloma field follows our lymphoma colleagues and demands randomized trials in this space. CAR T cells in particular shouldn\u2019t get moved into early lines without excellent evidence.", "lang": "en", "author_id": "626650397", "conversation_id": "1576208128626114560", "edit_history_tweet_ids": ["1576222131653734402"], "created_at": "2022-10-01T14:46:55.000Z", "in_reply_to_user_id": "1081903728"}, {"referenced_tweets": [{"type": "replied_to", "id": "1574698614395645952"}], "id": "1574916251771609088", "text": "@eliaseythorsson I\u2019ve had multiple conversations with one of our clinical pathology attendings and was also skeptical\u2026 but apparently it\u2019s not supported. You can put a note below with multiple reference intervals, but nobody reads it and it doesn\u2019t pop up as \u201cred\u201d", "lang": "en", "author_id": "626650397", "conversation_id": "1574576681238646785", "edit_history_tweet_ids": ["1574916251771609088"], "created_at": "2022-09-28T00:17:49.000Z", "entities": {"mentions": [{"start": 0, "end": 16, "username": "eliaseythorsson", "id": "133109181"}]}, "in_reply_to_user_id": "133109181"}, {"entities": {"annotations": [{"start": 37, "end": 43, "probability": 0.8663, "type": "Other", "normalized_text": "iStopMM"}], "urls": [{"start": 226, "end": 249, "url": "https://t.co/kxxmHAUlud", "expanded_url": "https://twitter.com/sykristinsson/status/1574422541711642625", "display_url": "twitter.com/sykristinsson/\u2026"}]}, "referenced_tweets": [{"type": "quoted", "id": "1574422541711642625"}], "id": "1574576681238646785", "text": "Interesting work from the phenomenal iStopMM group. This issue is that most EMRs (including Epic) don\u2019t support multiple reference intervals for one lab value. There are alternative approaches, one coming soon from our group! https://t.co/kxxmHAUlud", "lang": "en", "author_id": "626650397", "conversation_id": "1574576681238646785", "edit_history_tweet_ids": ["1574576681238646785"], "created_at": "2022-09-27T01:48:29.000Z"}, {"referenced_tweets": [{"type": "replied_to", "id": "1570551509506727936"}], "id": "1570826106978336770", "text": "@mpndoc @WUHemeOncFellow @WashUHeme @WashUDPS @WUDeptMedicine @dgermain21 @RPachynski @SanaSaifUrRehm We'll have to put these tweets up on the billboard in the fellows office. I can't be held responsible if someone brushes you back from the plate with a 10 mph slowball.", "lang": "en", "author_id": "626650397", "conversation_id": "1570551509506727936", "edit_history_tweet_ids": ["1570826106978336770"], "created_at": "2022-09-16T17:25:03.000Z", "entities": {"mentions": [{"start": 0, "end": 7, "username": "mpndoc", "id": "2930528191"}, {"start": 8, "end": 24, "username": "WUHemeOncFellow", "id": "1541500129399775234"}, {"start": 25, "end": 35, "username": "WashUHeme", "id": "1387867182609178624"}, {"start": 36, "end": 45, "username": "WashUDPS", "id": "1276507179575541761"}, {"start": 46, "end": 61, "username": "WUDeptMedicine", "id": "1105452868771946497"}, {"start": 62, "end": 73, "username": "dgermain21", "id": "18821994"}, {"start": 74, "end": 85, "username": "RPachynski", "id": "1179604816198275072"}, {"start": 86, "end": 101, "username": "SanaSaifUrRehm", "id": "1533874462503972865"}]}, "in_reply_to_user_id": "2930528191"}, {"id": "1557724431916892165", "text": "Every time I deal with the medical system as a patient, I\u2019m absolutely horrified.", "lang": "en", "author_id": "626650397", "conversation_id": "1557724431916892165", "edit_history_tweet_ids": ["1557724431916892165"], "created_at": "2022-08-11T13:43:40.000Z"}, {"referenced_tweets": [{"type": "replied_to", "id": "1553814327295098881"}], "id": "1556349616781656065", "text": "@romeerizwan @WashUIMRes @WUSTLmed @TimeOutBoston @DrHaleyEllis Absolutely amazing time (and amazing sushi tacos). Always great to see you offline!", "lang": "en", "author_id": "626650397", "conversation_id": "1553814327295098881", "edit_history_tweet_ids": ["1556349616781656065"], "created_at": "2022-08-07T18:40:38.000Z", "entities": {"mentions": [{"start": 0, "end": 12, "username": "romeerizwan", "id": "15622046"}, {"start": 13, "end": 24, "username": "WashUIMRes", "id": "1278033417096101888"}, {"start": 25, "end": 34, "username": "WUSTLmed", "id": "27779882"}, {"start": 35, "end": 49, "username": "TimeOutBoston", "id": "176449198"}, {"start": 50, "end": 63, "username": "DrHaleyEllis", "id": "764598685"}]}, "in_reply_to_user_id": "15622046"}, {"entities": {"annotations": [{"start": 96, "end": 99, "probability": 0.6115, "type": "Other", "normalized_text": "CD19"}], "mentions": [{"start": 3, "end": 19, "username": "NathanSinghLab1", "id": "1113150672894033921"}]}, "referenced_tweets": [{"type": "retweeted", "id": "1552359706521395200"}], "id": "1552475970686390273", "text": "RT @NathanSinghLab1: How small is too small? We identified that loss of a *single* codon in the CD19 locus led to antigen escape and CAR fa\u2026", "lang": "en", "author_id": "626650397", "conversation_id": "1552475970686390273", "edit_history_tweet_ids": ["1552475970686390273"], "created_at": "2022-07-28T02:08:09.000Z"}, {"referenced_tweets": [{"type": "replied_to", "id": "1552456804226981889"}], "id": "1552456814666588161", "entities": {"urls": [{"start": 0, "end": 23, "url": "https://t.co/g3LzETRs25", "expanded_url": "https://twitter.com/MichaelJSlade/status/1552456814666588161/photo/1", "display_url": "pic.twitter.com/g3LzETRs25", "media_key": "16_1552456807687360513"}]}, "text": "https://t.co/g3LzETRs25", "lang": "zxx", "author_id": "626650397", "conversation_id": "1552456804226981889", "edit_history_tweet_ids": ["1552456814666588161"], "created_at": "2022-07-28T00:52:02.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 37, "end": 45, "probability": 0.5878, "type": "Other", "normalized_text": "vitamin D"}], "urls": [{"start": 83, "end": 106, "url": "https://t.co/AUXMUq0xYu", "expanded_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2202106#.YuHdXrX5CDw.twitter", "display_url": "nejm.org/doi/full/10.10\u2026", "status": 200, "title": "Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults | NEJM", "description": "Original Article from The New England Journal of Medicine \u2014 Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults", "unwound_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2202106#.YuHdXrX5CDw.twitter"}]}, "id": "1552456804226981889", "text": "Another negative randomized trial of vitamin D supplementation in health adults? \n\nhttps://t.co/AUXMUq0xYu", "lang": "en", "author_id": "626650397", "conversation_id": "1552456804226981889", "edit_history_tweet_ids": ["1552456804226981889"], "created_at": "2022-07-28T00:52:00.000Z"}, {"entities": {"annotations": [{"start": 160, "end": 162, "probability": 0.5508, "type": "Other", "normalized_text": "MRD"}, {"start": 178, "end": 180, "probability": 0.5653, "type": "Other", "normalized_text": "MRD"}], "mentions": [{"start": 0, "end": 8, "username": "wangyub", "id": "2170278304"}, {"start": 9, "end": 18, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 19, "end": 34, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 35, "end": 51, "username": "RahulBanerjeeMD", "id": "26399236"}, {"start": 52, "end": 67, "username": "rajshekharucms", "id": "140966169"}, {"start": 68, "end": 80, "username": "HadidiSamer", "id": "774267564"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1551974678591246336"}], "id": "1551986969445548040", "text": "@wangyub @ManniMD1 @AaronGoodman33 @RahulBanerjeeMD @rajshekharucms @HadidiSamer I really enjoyed the nuanced discussion. I'm really hoping to see a randomized MRD-guided versus MRD-agnostic trial at some point here.", "lang": "en", "author_id": "626650397", "conversation_id": "1551973006288621568", "edit_history_tweet_ids": ["1551986969445548040"], "created_at": "2022-07-26T17:45:02.000Z", "in_reply_to_user_id": "2170278304"}, {"entities": {"annotations": [{"start": 89, "end": 95, "probability": 0.4616, "type": "Other", "normalized_text": "Twitter"}, {"start": 217, "end": 220, "probability": 0.5981, "type": "Organization", "normalized_text": "NCTN"}], "mentions": [{"start": 0, "end": 9, "username": "Geoff_Uy", "id": "985139345928736768"}, {"start": 10, "end": 22, "username": "joshuaafein", "id": "89023598"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1551965779436138497"}], "id": "1551981547938512896", "text": "@Geoff_Uy @joshuaafein I love the idea of recruiting the passion for trial design on Med Twitter into the existing infrastructure. What's the best route for early-career physicians to get hooked into their respective NCTN cooperative group?", "lang": "en", "author_id": "626650397", "conversation_id": "1551365116918202369", "edit_history_tweet_ids": ["1551981547938512896"], "created_at": "2022-07-26T17:23:30.000Z", "in_reply_to_user_id": "985139345928736768"}, {"referenced_tweets": [{"type": "retweeted", "id": "1550212787334529029"}], "id": "1550228252593209345", "text": "RT @WashUHeme: Applications are currently being accepted for our Fellowship program until 8/3/2022 at 11:59 CST. There are 8 Heme-Onc &amp; 1 H\u2026", "lang": "en", "author_id": "626650397", "conversation_id": "1550228252593209345", "edit_history_tweet_ids": ["1550228252593209345"], "created_at": "2022-07-21T21:16:31.000Z", "entities": {"mentions": [{"start": 3, "end": 13, "username": "WashUHeme", "id": "1387867182609178624"}]}}, {"referenced_tweets": [{"type": "replied_to", "id": "1550179700353507330"}], "id": "1550182714598457346", "text": "@Dr_AmerZeidan Never reply, they\u2019ll add you to the database of real numbers to spam.", "lang": "en", "author_id": "626650397", "conversation_id": "1550179700353507330", "edit_history_tweet_ids": ["1550182714598457346"], "created_at": "2022-07-21T18:15:34.000Z", "entities": {"mentions": [{"start": 0, "end": 14, "username": "Dr_AmerZeidan", "id": "1144997352148787201"}]}, "in_reply_to_user_id": "1144997352148787201"}, {"entities": {"annotations": [{"start": 80, "end": 86, "probability": 0.9588, "type": "Other", "normalized_text": "Twitter"}], "mentions": [{"start": 0, "end": 9, "username": "Geoff_Uy", "id": "985139345928736768"}, {"start": 10, "end": 20, "username": "jaltmanmd", "id": "2228604786"}, {"start": 21, "end": 36, "username": "Daver_Leukemia", "id": "2920960866"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1549960239969075201"}], "id": "1550181989122293760", "text": "@Geoff_Uy @jaltmanmd @Daver_Leukemia I am apparently terrible finding people on Twitter. Would love to hear from the co-authors!", "lang": "en", "author_id": "626650397", "conversation_id": "1549806764786421762", "edit_history_tweet_ids": ["1550181989122293760"], "created_at": "2022-07-21T18:12:41.000Z", "in_reply_to_user_id": "985139345928736768"}, {"entities": {"annotations": [{"start": 45, "end": 54, "probability": 0.6247, "type": "Other", "normalized_text": "venetoclax"}, {"start": 63, "end": 67, "probability": 0.7648, "type": "Other", "normalized_text": "FLT3i"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1549806766959075328"}], "id": "1549806768842330113", "text": "Also, props to trialists for including prior venetoclax, prior FLT3i (except gilt) and prior transplant. This is not a cherry-picked population.", "lang": "en", "author_id": "626650397", "conversation_id": "1549806764786421762", "edit_history_tweet_ids": ["1549806768842330113"], "created_at": "2022-07-20T17:21:42.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 116, "end": 119, "probability": 0.5814, "type": "Other", "normalized_text": "MLFS"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1549806764786421762"}], "id": "1549806766959075328", "text": "I wouldn't fixate on this except that almost half of the \"modified composite complete response\" patients (75%) were MLFS only (36%). This is a tough population to treat/recruit. Getting to 39% CR + CRi isn't bad (albeit with a ton of cytopenias). Just a weird primary endpoint.", "lang": "en", "author_id": "626650397", "conversation_id": "1549806764786421762", "edit_history_tweet_ids": ["1549806766959075328"], "created_at": "2022-07-20T17:21:41.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 71, "end": 90, "probability": 0.5042, "type": "Other", "normalized_text": "morphologic leukemia"}, {"start": 104, "end": 107, "probability": 0.5295, "type": "Other", "normalized_text": "MLFS"}, {"start": 185, "end": 188, "probability": 0.5716, "type": "Other", "normalized_text": "MLFS"}, {"start": 209, "end": 212, "probability": 0.7057, "type": "Other", "normalized_text": "NEJM"}], "urls": [{"start": 253, "end": 276, "url": "https://t.co/QdUgLbC95x", "expanded_url": "https://ascopubs.org/doi/full/10.1200/JCO.22.00602?bid=186376274&cid=DM11069", "display_url": "ascopubs.org/doi/full/10.12\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1549806807383695361/WbNiRweH?format=png&name=orig", "width": 269, "height": 269}, {"url": "https://pbs.twimg.com/news_img/1549806807383695361/WbNiRweH?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia", "description": "PURPOSE The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy for relapsed/refractory FLT3-mutated (FLT3mut) acute myeloid leukemia (AML) but seldom reduces FLT3mut burden or induces sustained efficacy. Gilteritinib combines synergistically with the BCL-2 inhibitor venetoclax in preclinical models of FLT3mut AML. METHODS This phase Ib open-label, dose-escalation/dose-expansion study (ClinicalTrials.gov identifier: NCT03625505) enrolled patients with FLT3 wild-type and FLT3mut (escalation) or FLT3mut (expansion) relapsed/refractory AML. Patients received 400 mg oral venetoclax once daily and 80 mg or 120 mg oral gilteritinib once daily. The primary objectives were safety, identification of the recommended phase II dose, and the modified composite complete response (mCRc) rate (complete response [CR] + CR with incomplete blood count recovery + CR with incomplete platelet recovery + morphologic leukemia-free state) using ADMIRAL phase III\u2013defined response cri", "unwound_url": "https://ascopubs.org/doi/full/10.1200/JCO.22.00602?bid=186376274&cid=DM11069"}]}, "id": "1549806764786421762", "text": "What's going on with the response criteria in this trial? They include morphologic leukemia-free state (MLFS) in the composite endpoint and keep referencing the \"ADMIRAL criteria.\" But MLFS is not in the 2019 NEJM manuscript, supplement or protocol.  \n\nhttps://t.co/QdUgLbC95x", "lang": "en", "author_id": "626650397", "conversation_id": "1549806764786421762", "edit_history_tweet_ids": ["1549806764786421762"], "created_at": "2022-07-20T17:21:41.000Z"}, {"entities": {"annotations": [{"start": 43, "end": 56, "probability": 0.6428, "type": "Person", "normalized_text": "Timothy J. Ley"}, {"start": 108, "end": 127, "probability": 0.701, "type": "Other", "normalized_text": "Henry Stratton Medal"}], "mentions": [{"start": 3, "end": 17, "username": "SitemanCenter", "id": "89517086"}, {"start": 20, "end": 29, "username": "WUSTLmed", "id": "27779882"}, {"start": 83, "end": 98, "username": "ASH_hematology", "id": "84072624"}]}, "referenced_tweets": [{"type": "retweeted", "id": "1549001422326403072"}], "id": "1549083645612376064", "text": "RT @SitemanCenter: .@WUSTLmed hematologist Timothy J. Ley, MD, has been honored by @ASH_hematology with the Henry Stratton Medal. The award\u2026", "lang": "en", "author_id": "626650397", "conversation_id": "1549083645612376064", "edit_history_tweet_ids": ["1549083645612376064"], "created_at": "2022-07-18T17:28:16.000Z"}, {"referenced_tweets": [{"type": "replied_to", "id": "1549039706465521664"}], "id": "1549040733847703553", "entities": {"urls": [{"start": 85, "end": 108, "url": "https://t.co/RvOpafdyNF", "expanded_url": "https://www.tandfonline.com/eprint/WPU4VAQR6TCUAIS3EARF/full?target=10.1080/10428194.2022.2100367", "display_url": "tandfonline.com/eprint/WPU4VAQ\u2026", "status": 200, "title": "The impact of tocilizumab treatment for cytokine release syndrome on the incidence of early blood stream infections after peripheral blood haploidentical hematopoietic cell transplantation", "description": "Cytokine release syndrome (CRS) is a potentially fatal systemic inflammatory response that can occur in patients undergoing peripheral blood haploidentical hematopoietic cell transplantation (haplo...", "unwound_url": "https://www.tandfonline.com/eprint/WPU4VAQR6TCUAIS3EARF/full?target=10.1080/10428194.2022.2100367"}]}, "text": "Free e-prints at link below if you don't have institutional access to this journal:\n\nhttps://t.co/RvOpafdyNF", "lang": "en", "author_id": "626650397", "conversation_id": "1549039706465521664", "edit_history_tweet_ids": ["1549040733847703553"], "created_at": "2022-07-18T14:37:45.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 63, "end": 70, "probability": 0.6062, "type": "Other", "normalized_text": "De Togni"}, {"start": 138, "end": 140, "probability": 0.5042, "type": "Other", "normalized_text": "CRS"}, {"start": 153, "end": 153, "probability": 0.4847, "type": "Other", "normalized_text": "-"}], "urls": [{"start": 231, "end": 254, "url": "https://t.co/q9IrVDEVrw", "expanded_url": "https://tinyurl.com/mrxv9e6p", "display_url": "tinyurl.com/mrxv9e6p", "images": [{"url": "https://pbs.twimg.com/news_img/1549039711414816768/b6FXp9_0?format=jpg&name=orig", "width": 555, "height": 723}, {"url": "https://pbs.twimg.com/news_img/1549039711414816768/b6FXp9_0?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "The impact of tocilizumab treatment for cytokine release syndrome on the incidence of early blood stream infections after peripheral blood haploidentical hematopoietic cell transplantation", "description": "Cytokine release syndrome (CRS) is a potentially fatal systemic inflammatory response that can occur in patients undergoing peripheral blood haploidentical hematopoietic cell transplantation (haplo...", "unwound_url": "https://www.tandfonline.com/doi/full/10.1080/10428194.2022.2100367"}], "mentions": [{"start": 36, "end": 47, "username": "WashUIMRes", "id": "1278033417096101888"}, {"start": 173, "end": 182, "username": "ramziabb", "id": "889186404"}, {"start": 216, "end": 228, "username": "romeerizwan", "id": "15622046"}]}, "id": "1549039706465521664", "text": "Strong work by one of our fantastic @WashUIMRes residents, Dr. De Togni, looking at the impact on infection risk of early tocilizumab for CRS after haplo-HCT. \n\nMentored by @ramziabb, continuing work he started with @romeerizwan.\n\nhttps://t.co/q9IrVDEVrw", "lang": "en", "author_id": "626650397", "conversation_id": "1549039706465521664", "edit_history_tweet_ids": ["1549039706465521664"], "created_at": "2022-07-18T14:33:40.000Z"}, {"entities": {"annotations": [{"start": 46, "end": 52, "probability": 0.6651, "type": "Other", "normalized_text": "myeloma"}, {"start": 71, "end": 73, "probability": 0.5341, "type": "Other", "normalized_text": "KRd"}, {"start": 79, "end": 81, "probability": 0.589, "type": "Other", "normalized_text": "VRd"}], "urls": [{"start": 188, "end": 211, "url": "https://t.co/FhMAC2NjUk", "expanded_url": "https://tinyurl.com/bddeksz6", "display_url": "tinyurl.com/bddeksz6", "unwound_url": "https://www.nature.com/articles/s41409-022-01697-4?utm_source=bmt_etoc&utm_medium=email&utm_campaign=toc_41409_57_7&utm_content=20220708&error=cookies_not_supported&code=16d0e8de-7ed1-4fd9-b490-0fcf1cec9ab6"}], "mentions": [{"start": 30, "end": 45, "username": "MDAndersonNews", "id": "14062554"}]}, "id": "1546224168278102016", "text": "Nice retrospective paper from @MDAndersonNews myeloma group looking at KRd vs. VRd induction -&gt; ASCT for high cytogenetic risk NDMM. \n\nTL/DR: no detectable difference in outcomes.    \n\nhttps://t.co/FhMAC2NjUk", "lang": "en", "author_id": "626650397", "conversation_id": "1546224168278102016", "edit_history_tweet_ids": ["1546224168278102016"], "created_at": "2022-07-10T20:05:43.000Z"}, {"referenced_tweets": [{"type": "quoted", "id": "1544719941873590272"}], "id": "1545134999464198145", "entities": {"urls": [{"start": 41, "end": 64, "url": "https://t.co/T71tUJt470", "expanded_url": "https://twitter.com/mpndoc/status/1544719941873590272", "display_url": "twitter.com/mpndoc/status/\u2026"}]}, "text": "Hey, I know that (incredibly smart) guy! https://t.co/T71tUJt470", "lang": "en", "author_id": "626650397", "conversation_id": "1545134999464198145", "edit_history_tweet_ids": ["1545134999464198145"], "created_at": "2022-07-07T19:57:45.000Z"}, {"referenced_tweets": [{"type": "replied_to", "id": "1544336266216472580"}], "id": "1544352289640648706", "text": "@NicoGagelmann @nihardesai7 @PanktiMehta24 @GomezDLeonMD @AbbasiMuqtadir @BijoyTelivala @CyrilPedia @chano_py @YasSerroukh @Nephro_Sparks @NephJC How long does it generally take to come back?", "lang": "en", "author_id": "626650397", "conversation_id": "1544336266216472580", "edit_history_tweet_ids": ["1544352289640648706"], "created_at": "2022-07-05T16:07:33.000Z", "entities": {"mentions": [{"start": 0, "end": 14, "username": "NicoGagelmann", "id": "1054759355512438786"}, {"start": 15, "end": 27, "username": "nihardesai7", "id": "75550503"}, {"start": 28, "end": 42, "username": "PanktiMehta24", "id": "1186112061232861186"}, {"start": 43, "end": 56, "username": "GomezDLeonMD", "id": "1039939970415218688"}, {"start": 57, "end": 72, "username": "AbbasiMuqtadir", "id": "1017795284905144322"}, {"start": 73, "end": 87, "username": "BijoyTelivala", "id": "964268621655695360"}, {"start": 88, "end": 99, "username": "CyrilPedia", "id": "4160274844"}, {"start": 100, "end": 109, "username": "chano_py", "id": "327027686"}, {"start": 110, "end": 122, "username": "YasSerroukh", "id": "160565469"}, {"start": 123, "end": 137, "username": "Nephro_Sparks", "id": "24415922"}, {"start": 138, "end": 145, "username": "NephJC", "id": "2449899066"}]}, "in_reply_to_user_id": "1054759355512438786"}, {"referenced_tweets": [{"type": "replied_to", "id": "1542899870503211016"}], "id": "1543656486349545477", "text": "@angryfermion Your online training modules are overdue", "lang": "en", "author_id": "626650397", "conversation_id": "1542899870503211016", "edit_history_tweet_ids": ["1543656486349545477"], "created_at": "2022-07-03T18:02:40.000Z", "entities": {"mentions": [{"start": 0, "end": 13, "username": "angryfermion", "id": "1477363087737032708"}]}, "in_reply_to_user_id": "1477363087737032708"}, {"entities": {"annotations": [{"start": 27, "end": 35, "probability": 0.422, "type": "Person", "normalized_text": "Sisyphean"}]}, "id": "1543607512758472706", "text": "Every weekend feels like a Sisyphean struggle against household entropy.", "lang": "en", "author_id": "626650397", "conversation_id": "1543607512758472706", "edit_history_tweet_ids": ["1543607512758472706"], "created_at": "2022-07-03T14:48:04.000Z"}, {"id": "1542231388811939840", "entities": {"urls": [{"start": 189, "end": 212, "url": "https://t.co/t1WR66QooE", "expanded_url": "https://tinyurl.com/mvyemjhr", "display_url": "tinyurl.com/mvyemjhr", "status": 404, "unwound_url": "https://www.hematology.org/404?item=%2fadvocacy%2freach-out-to-congress%2ftell-your-elected-officials-protect-access-to-health-care&user=extranet%5cAnonymous&site=hematology"}], "mentions": [{"start": 48, "end": 52, "username": "Ash", "id": "5355992"}]}, "text": "In case you missed it:\n\nPlease consider joining @ASH to advocate for the right to maternal health care for our patients. It is a tiny drop of something under a waves of feeling helpless. \n\nhttps://t.co/t1WR66QooE", "lang": "en", "author_id": "626650397", "conversation_id": "1542231388811939840", "edit_history_tweet_ids": ["1542231388811939840"], "created_at": "2022-06-29T19:39:51.000Z"}, {"entities": {"annotations": [{"start": 63, "end": 65, "probability": 0.6336, "type": "Other", "normalized_text": "MRD"}, {"start": 87, "end": 89, "probability": 0.6065, "type": "Other", "normalized_text": "MRD"}, {"start": 124, "end": 125, "probability": 0.9401, "type": "Place", "normalized_text": "US"}, {"start": 178, "end": 181, "probability": 0.7399, "type": "Other", "normalized_text": "GVHD"}, {"start": 183, "end": 185, "probability": 0.6159, "type": "Other", "normalized_text": "TRM"}], "mentions": [{"start": 0, "end": 13, "username": "GomezDLeonMD", "id": "1039939970415218688"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1541889275448508416"}], "id": "1542121730478587905", "text": "@GomezDLeonMD Very patient specific. Limited data on sustained MRD but even with early MRD transplant doesn\u2019t improve OS in US setting. However, does decrease relapse at cost of GVHD/TRM. If patient feels strongly, understands r/b and has good donor, would transplant.", "lang": "en", "author_id": "626650397", "conversation_id": "1541889275448508416", "edit_history_tweet_ids": ["1542121730478587905"], "created_at": "2022-06-29T12:24:06.000Z", "in_reply_to_user_id": "1039939970415218688"}, {"referenced_tweets": [{"type": "replied_to", "id": "1540806938237276161"}], "id": "1540823809560911872", "text": "@drjessigold @CalculatingMind I also worry this means that being officially \u201cmentally sick\u201d enough to access abortion means you are also likely to lose any other children you have to the state, which puts women in the horns of a horrific dilemma.", "lang": "en", "author_id": "626650397", "conversation_id": "1540769555924062208", "edit_history_tweet_ids": ["1540823809560911872"], "created_at": "2022-06-25T22:26:37.000Z", "entities": {"mentions": [{"start": 0, "end": 12, "username": "drjessigold", "id": "785968989092446209"}, {"start": 13, "end": 29, "username": "CalculatingMind", "id": "4821114131"}]}, "in_reply_to_user_id": "785968989092446209"}, {"referenced_tweets": [{"type": "replied_to", "id": "1540708075291627520"}], "id": "1540713691292860416", "text": "@MyelomaAmateur @bdermanmd @docbraunstein You\u2019re 100% right that this is not well captured by standard terms. You generally have to dive into the methods of the trial (or sometimes the supplement) to figure out what definition is being used.", "lang": "en", "author_id": "626650397", "conversation_id": "1540701933425504256", "edit_history_tweet_ids": ["1540713691292860416"], "created_at": "2022-06-25T15:09:03.000Z", "entities": {"mentions": [{"start": 0, "end": 15, "username": "MyelomaAmateur", "id": "1302975798304014336"}, {"start": 16, "end": 26, "username": "bdermanmd", "id": "872983600416862208"}, {"start": 27, "end": 41, "username": "docbraunstein", "id": "2333504019"}]}, "in_reply_to_user_id": "1302975798304014336"}, {"referenced_tweets": [{"type": "replied_to", "id": "1540433736050827264"}], "id": "1540437724989112327", "text": "@michaelgscott37 No rhetoric. I just know some physicians who practiced pre-Roe and had some back alley abortion cases they were absolutely scarred by.", "lang": "en", "author_id": "626650397", "conversation_id": "1540427622093623296", "edit_history_tweet_ids": ["1540437724989112327"], "created_at": "2022-06-24T20:52:28.000Z", "in_reply_to_user_id": "1508704605173133315"}, {"id": "1540427622093623296", "text": "I now live in a state with no legal abortion. I wonder how long it\u2019ll be before a young woman dies in our ER from complications of an illegal one.", "lang": "en", "author_id": "626650397", "conversation_id": "1540427622093623296", "edit_history_tweet_ids": ["1540427622093623296"], "created_at": "2022-06-24T20:12:19.000Z"}, {"entities": {"annotations": [{"start": 194, "end": 196, "probability": 0.4589, "type": "Other", "normalized_text": "CPH"}], "urls": [{"start": 36, "end": 59, "url": "https://t.co/RQ9Xg9Zrwk", "expanded_url": "https://web.njit.edu/~wguo/Math%20659_2010/Chapters%205%20and%206%20%20from%20%5BSurvival%20Analysis_A%20Self%20Learning%20Text_Book%5D.pdf", "display_url": "web.njit.edu/~wguo/Math%206\u2026", "status": 200, "unwound_url": "https://web.njit.edu/~wguo/Math%20659_2010/Chapters%205%20and%206%20%20from%20%5BSurvival%20Analysis_A%20Self%20Learning%20Text_Book%5D.pdf"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1539729114051084288"}], "id": "1539731516070174720", "text": "Found a great reference for this: \n\nhttps://t.co/RQ9Xg9Zrwk\n\nAnswer: yes and the trial level variable may violate the proportional hazards assumption (hence stratifying and not including in the CPH)", "lang": "en", "author_id": "626650397", "conversation_id": "1539729112809570306", "edit_history_tweet_ids": ["1539731516070174720"], "created_at": "2022-06-22T22:06:14.000Z", "in_reply_to_user_id": "626650397"}, {"referenced_tweets": [{"type": "replied_to", "id": "1539729112809570306"}], "id": "1539729114051084288", "text": "Would stratifying the models\nby trial be enough to compensate for this effect?", "lang": "en", "author_id": "626650397", "conversation_id": "1539729112809570306", "edit_history_tweet_ids": ["1539729114051084288"], "created_at": "2022-06-22T21:56:42.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 107, "end": 110, "probability": 0.3683, "type": "Organization", "normalized_text": "NDMM"}], "urls": [{"start": 242, "end": 265, "url": "https://t.co/zYVgl8cEGo", "expanded_url": "https://tinyurl.com/5ct4fdp2", "display_url": "tinyurl.com/5ct4fdp2", "images": [{"url": "https://pbs.twimg.com/news_img/1539729119717597191/VXAMxF_1?format=png&name=orig", "width": 520, "height": 685}, {"url": "https://pbs.twimg.com/news_img/1539729119717597191/VXAMxF_1?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials", "description": "Key Points. Black and Hispanic patients are underrepresented in global MM clinical trials.Black patients enrolled in the United States had better survival outco", "unwound_url": "https://ashpublications.org/bloodadvances/article/6/6/1684/483828/Analysis-of-racial-and-ethnic-disparities-in"}], "mentions": [{"start": 34, "end": 48, "username": "BloodAdvances", "id": "732570175162179585"}]}, "id": "1539729112809570306", "text": "Reading this (important) paper in @BloodAdvances and I can\u2019t figure out if they adjusted for enrollment in NDMM vs R/R MM trials. 92% of AA vs 68% of white pts were enrolled in R/R trials and likely significant confounding if not adjusted. \n\nhttps://t.co/zYVgl8cEGo", "lang": "en", "author_id": "626650397", "conversation_id": "1539729112809570306", "edit_history_tweet_ids": ["1539729112809570306"], "created_at": "2022-06-22T21:56:41.000Z"}, {"entities": {"annotations": [{"start": 31, "end": 40, "probability": 0.894, "type": "Person", "normalized_text": "Miriam Kim"}, {"start": 134, "end": 138, "probability": 0.7708, "type": "Other", "normalized_text": "NT-I7"}], "mentions": [{"start": 3, "end": 12, "username": "Geoff_Uy", "id": "985139345928736768"}, {"start": 46, "end": 58, "username": "DiPersioLab", "id": "1349142172415762433"}, {"start": 62, "end": 74, "username": "NatureComms", "id": "206255645"}]}, "referenced_tweets": [{"type": "retweeted", "id": "1539563616290197506"}], "id": "1539714863815184384", "text": "RT @Geoff_Uy: New paper out by Miriam Kim and @DiPersioLab in @NatureComms showing how to enhance CART expansion and persistence with NT-I7\u2026", "lang": "en", "author_id": "626650397", "conversation_id": "1539714863815184384", "edit_history_tweet_ids": ["1539714863815184384"], "created_at": "2022-06-22T21:00:04.000Z"}, {"entities": {"annotations": [{"start": 134, "end": 136, "probability": 0.5435, "type": "Other", "normalized_text": "PFS"}, {"start": 166, "end": 168, "probability": 0.5735, "type": "Other", "normalized_text": "KRd"}], "mentions": [{"start": 0, "end": 13, "username": "Abdallah81MD", "id": "1026947037080772610"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1538403464275009538"}], "id": "1538720970864840704", "text": "@Abdallah81MD I\u2019m interested to dive into the data tables when this manuscript is published. It\u2019ll take a lot to convince me that any PFS benefit is worth 3 years of KRd. And an OS benefit if the control doesn\u2019t get K on progression is worthless.", "lang": "en", "author_id": "626650397", "conversation_id": "1538403462836256768", "edit_history_tweet_ids": ["1538720970864840704"], "created_at": "2022-06-20T03:10:42.000Z", "in_reply_to_user_id": "1026947037080772610"}, {"referenced_tweets": [{"type": "replied_to", "id": "1538186242730340352"}], "id": "1538605787358052355", "text": "@Sthanu5 @AaronGoodman33 POEMSPEST\u2026 I love it. Never seen the acronym for the other minor criteria before.", "lang": "en", "author_id": "626650397", "conversation_id": "1538162492022484992", "edit_history_tweet_ids": ["1538605787358052355"], "created_at": "2022-06-19T19:33:00.000Z", "entities": {"mentions": [{"start": 0, "end": 8, "username": "Sthanu5", "id": "821765042051784705"}, {"start": 9, "end": 24, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "in_reply_to_user_id": "821765042051784705"}, {"referenced_tweets": [{"type": "replied_to", "id": "1537955855470977024"}], "id": "1537998884500189184", "text": "@Geoff_Uy @CyclingDoctor @dgermain21 @mpndoc @VPrasadMDMPH @NTrikalinos @RPachynski I love the range of opinions on this. To clarify, I feel that 80% of reviewer comments are fair, helpful and improve the manuscript. The other 20% are often things I\u2019d love to explore if I wasn\u2019t fighting to stay under the word limit. Thanks everyone for the input!", "lang": "en", "author_id": "626650397", "conversation_id": "1537806644863807488", "edit_history_tweet_ids": ["1537998884500189184"], "created_at": "2022-06-18T03:21:23.000Z", "entities": {"mentions": [{"start": 0, "end": 9, "username": "Geoff_Uy", "id": "985139345928736768"}, {"start": 10, "end": 24, "username": "CyclingDoctor", "id": "23036480"}, {"start": 25, "end": 36, "username": "dgermain21", "id": "18821994"}, {"start": 37, "end": 44, "username": "mpndoc", "id": "2930528191"}, {"start": 45, "end": 58, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 59, "end": 71, "username": "NTrikalinos", "id": "1242826524010651653"}, {"start": 72, "end": 83, "username": "RPachynski", "id": "1179604816198275072"}]}, "in_reply_to_user_id": "985139345928736768"}, {"referenced_tweets": [{"type": "replied_to", "id": "1537689553821212680"}], "id": "1537860464973168643", "text": "@BijoyTelivala I love it. Bring a good book and bask in the absence of email.", "lang": "en", "author_id": "626650397", "conversation_id": "1537689553821212680", "edit_history_tweet_ids": ["1537860464973168643"], "created_at": "2022-06-17T18:11:21.000Z", "entities": {"mentions": [{"start": 0, "end": 14, "username": "BijoyTelivala", "id": "964268621655695360"}]}, "in_reply_to_user_id": "964268621655695360"}, {"referenced_tweets": [{"type": "replied_to", "id": "1537812980082954245"}], "id": "1537860068556918785", "text": "@ManniMD1 A quibble: the issue with a per-protocol analysis is that patients who are randomized to an arm but don\u2019t receive the prescribed therapy are a different population than the patients that followed the protocol (sicker, etc). You torpedo randomization. \n\nAs always, great thread.", "lang": "en", "author_id": "626650397", "conversation_id": "1537812935845629955", "edit_history_tweet_ids": ["1537860068556918785"], "created_at": "2022-06-17T18:09:47.000Z", "entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}]}, "in_reply_to_user_id": "1269642863924609025"}, {"referenced_tweets": [{"type": "replied_to", "id": "1537808433302355969"}], "id": "1537808434741096450", "text": "@CyclingDoctor @dgermain21 @Geoff_Uy @mpndoc @VPrasadMDMPH @NTrikalinos @RPachynski", "lang": "qam", "author_id": "626650397", "conversation_id": "1537806644863807488", "edit_history_tweet_ids": ["1537808434741096450"], "created_at": "2022-06-17T14:44:36.000Z", "entities": {"mentions": [{"start": 0, "end": 14, "username": "CyclingDoctor", "id": "23036480"}, {"start": 15, "end": 26, "username": "dgermain21", "id": "18821994"}, {"start": 27, "end": 36, "username": "Geoff_Uy", "id": "985139345928736768"}, {"start": 37, "end": 44, "username": "mpndoc", "id": "2930528191"}, {"start": 45, "end": 58, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 59, "end": 71, "username": "NTrikalinos", "id": "1242826524010651653"}, {"start": 72, "end": 83, "username": "RPachynski", "id": "1179604816198275072"}]}, "in_reply_to_user_id": "626650397"}, {"referenced_tweets": [{"type": "replied_to", "id": "1537806644863807488"}], "id": "1537808433302355969", "text": "And I don't mean \"You have a typo\", \"Please add data on X\" or \"You didn't acknowledge this limitation\" type comments. I'm talking \"Please re-focus discussion on Y\" or \"Cite and discuss specific paper Z\"", "lang": "en", "author_id": "626650397", "conversation_id": "1537806644863807488", "edit_history_tweet_ids": ["1537808433302355969"], "created_at": "2022-06-17T14:44:36.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 1, "end": 10, "probability": 0.8841, "type": "Other", "normalized_text": "MedTwitter"}], "hashtags": [{"start": 0, "end": 11, "tag": "MedTwitter"}]}, "id": "1537806644863807488", "text": "#MedTwitter, please advise\n\nScenario: \n\nYour paper is rejected (without revision) from journal #1. Journal #2 requires you submit prior reviewer comments if considered for publication elsewhere. \n\nQuestion:\n\nAre you obligated to address all the reviewer concerns from journal #1?", "lang": "en", "author_id": "626650397", "conversation_id": "1537806644863807488", "edit_history_tweet_ids": ["1537806644863807488"], "created_at": "2022-06-17T14:37:29.000Z"}, {"referenced_tweets": [{"type": "quoted", "id": "1537646806535897090"}], "id": "1537805434651803650", "entities": {"urls": [{"start": 19, "end": 42, "url": "https://t.co/x4f6EVJzZS", "expanded_url": "https://twitter.com/mpndoc/status/1537646806535897090", "display_url": "twitter.com/mpndoc/status/\u2026"}]}, "text": "An incredible team https://t.co/x4f6EVJzZS", "lang": "en", "author_id": "626650397", "conversation_id": "1537805434651803650", "edit_history_tweet_ids": ["1537805434651803650"], "created_at": "2022-06-17T14:32:41.000Z"}], "includes": {"users": [{"id": "626650397", "name": "Michael Slade, MD", "username": "MichaelJSlade"}, {"id": "18821994", "name": "David Russler-Germain, MD/PhD", "username": "dgermain21"}, {"id": "24261916", "name": "Vincent Rajkumar", "username": "VincentRK"}, {"id": "3025849894", "name": "Juda Lebow MD", "username": "judalebow"}, {"id": "190337035", "name": "Mike Thompson, MD, PhD, FASCO", "username": "mtmdphd"}, {"id": "1283867959979630596", "name": "Louis Williams", "username": "LouisWilliamsMD"}, {"id": "26399236", "name": "Rahul Banerjee, MD, FACP", "username": "RahulBanerjeeMD"}, {"id": "1026947037080772610", "name": "Al-Ola A Abdallah MD", "username": "Abdallah81MD"}, {"id": "1269642863924609025", "name": "Manni Mohyuddin", "username": "ManniMD1"}, {"id": "1054759355512438786", "name": "Nico Gagelmann", "username": "NicoGagelmann"}, {"id": "23036480", "name": "Keith Stockerl-Goldstein, MD \ud83d\ude37", "username": "CyclingDoctor"}, {"id": "1039939970415218688", "name": "Andres Gomez", "username": "GomezDLeonMD"}, {"id": "3206254672", "name": "John Sisino", "username": "smarmyEOD"}, {"id": "919588789827203072", "name": "Simon Boyi Chen", "username": "simonbchen"}, {"id": "854692626015993857", "name": "Aaron Goodman - \u201cPapa Heme\u201d", "username": "AaronGoodman33"}, {"id": "826584913214316546", "name": "Nicholas Short MD", "username": "NicholasShortMD"}, {"id": "1081903728", "name": "Krishna Komanduri, MD, FASTCT \ud83c\uddfa\ud83c\udde6", "username": "drkomanduri"}, {"id": "133109181", "name": "El\u00edas Ey\u00fe\u00f3rsson", "username": "eliaseythorsson"}, {"id": "2930528191", "name": "Stephen Oh", "username": "mpndoc"}, {"id": "15622046", "name": "Rizwan Romee", "username": "romeerizwan"}, {"id": "2170278304", "name": "ABQ Runner", "username": "wangyub"}, {"id": "985139345928736768", "name": "Geoffrey Uy", "username": "Geoff_Uy"}, {"id": "1144997352148787201", "name": "Amer Zeidan MBBS,MHS \u200f\u0639\u0627\u0645\u0631 \u0632\u064a\u062f\u0627\u0646", "username": "Dr_AmerZeidan"}, {"id": "1477363087737032708", "name": "\ud83d\ude21fermion", "username": "angryfermion"}, {"id": "785968989092446209", "name": "Jessi Gold MD MS", "username": "drjessigold"}, {"id": "1302975798304014336", "name": "Kate", "username": "MyelomaAmateur"}, {"id": "1508704605173133315", "name": "socratesjohnson", "username": "sew_cratesJ"}, {"id": "821765042051784705", "name": "Sthanu", "username": "Sthanu5"}, {"id": "964268621655695360", "name": "Bijoy Telivala", "username": "BijoyTelivala"}], "tweets": [{"entities": {"annotations": [{"start": 27, "end": 31, "probability": 0.6051, "type": "Other", "normalized_text": "ASH22"}], "hashtags": [{"start": 26, "end": 32, "tag": "ASH22"}], "urls": [{"start": 213, "end": 236, "url": "https://t.co/7GI03QjHlz", "expanded_url": "https://oncologyprotocols.wustl.edu/WU_ASH2022_abstracts.html", "display_url": "oncologyprotocols.wustl.edu/WU_ASH2022_abs\u2026", "status": 200, "title": "2022 Washington University ASH Abstract", "unwound_url": "https://oncologyprotocols.wustl.edu/WU_ASH2022_abstracts.html"}], "mentions": [{"start": 48, "end": 57, "username": "WUSTLmed", "id": "27779882"}, {"start": 82, "end": 98, "username": "WUHemeOncFellow", "id": "1541500129399775234"}, {"start": 101, "end": 116, "username": "SanaSaifUrRehm", "id": "1533874462503972865"}, {"start": 117, "end": 131, "username": "MichaelJSlade", "id": "626650397"}, {"start": 132, "end": 143, "username": "dgermain21", "id": "18821994"}, {"start": 144, "end": 160, "username": "NehaMehtaShahMD", "id": "940415886401458176"}, {"start": 161, "end": 168, "username": "mpndoc", "id": "2930528191"}, {"start": 169, "end": 180, "username": "challenlab", "id": "906961052365197312"}, {"start": 181, "end": 196, "username": "NathanSinghLab", "id": "1113150672894033921"}, {"start": 197, "end": 210, "username": "KellyLBolton", "id": "1108468287036407808"}]}, "id": "1600947865161199616", "text": "Check out some of the \ud835\udfed\ud835\udff1\ud835\udfee #ASH22 abstracts from @WUSTLmed including many from our @WUHemeOncFellow \n\n@SanaSaifUrRehm @MichaelJSlade @dgermain21 @NehaMehtaShahMD @mpndoc\n@challenlab @NathanSinghLab @KellyLBolton \n\nhttps://t.co/7GI03QjHlz", "lang": "en", "author_id": "23036480", "conversation_id": "1600947865161199616", "edit_history_tweet_ids": ["1600947865161199616"], "created_at": "2022-12-08T20:18:09.000Z"}, {"referenced_tweets": [{"type": "replied_to", "id": "1600594348558921728"}], "id": "1600594512774311937", "text": "@TheWonkologist Not that I\u2019m aware of, but I\u2019ve been going off on this point for the last year here at our program :)", "lang": "en", "author_id": "18821994", "conversation_id": "1600574596566106156", "edit_history_tweet_ids": ["1600594512774311937"], "created_at": "2022-12-07T20:54:04.000Z", "entities": {"mentions": [{"start": 0, "end": 15, "username": "TheWonkologist", "id": "3234116877"}]}, "in_reply_to_user_id": "3234116877"}, {"referenced_tweets": [{"type": "replied_to", "id": "1600659677607591936"}], "id": "1600675917986115584", "text": "@mtmdphd This is great! Dumb question: as a tech illiterate\u2026 what does the \u201csm\u201d in all these hashtags stand for?", "lang": "en", "author_id": "626650397", "conversation_id": "1600642889280798721", "edit_history_tweet_ids": ["1600675917986115584"], "created_at": "2022-12-08T02:17:32.000Z", "entities": {"mentions": [{"start": 0, "end": 8, "username": "mtmdphd", "id": "190337035"}]}, "in_reply_to_user_id": "190337035"}, {"entities": {"annotations": [{"start": 216, "end": 222, "probability": 0.6069, "type": "Other", "normalized_text": "myeloma"}], "mentions": [{"start": 0, "end": 14, "username": "MichaelJSlade", "id": "626650397"}, {"start": 15, "end": 29, "username": "CyclingDoctor", "id": "23036480"}, {"start": 30, "end": 42, "username": "LabFehniger", "id": "1198731683199098881"}, {"start": 43, "end": 55, "username": "DiPersioLab", "id": "1349142172415762433"}, {"start": 56, "end": 71, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 72, "end": 81, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 82, "end": 96, "username": "DavidSteensma", "id": "2739065578"}, {"start": 97, "end": 107, "username": "bdermanmd", "id": "872983600416862208"}, {"start": 108, "end": 121, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 122, "end": 132, "username": "myelomaMD", "id": "301568235"}, {"start": 133, "end": 142, "username": "Geoff_Uy", "id": "985139345928736768"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1600642889280798721"}], "id": "1600673744728489984", "text": "@MichaelJSlade @CyclingDoctor @LabFehniger @DiPersioLab @AaronGoodman33 @ManniMD1 @DavidSteensma @bdermanmd @VPrasadMDMPH @myelomaMD @Geoff_Uy I usually apply the oral session filter and the field I\u2019m interested in (myeloma) and quickly scan through the abstracts, printing ones I feel are important for me. The exercise then of picking my top 5 each year ensures I read the ones I print (about ~25) closely.", "lang": "en", "author_id": "24261916", "conversation_id": "1600642889280798721", "edit_history_tweet_ids": ["1600673744728489984"], "created_at": "2022-12-08T02:08:54.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 277, "end": 283, "probability": 0.5864, "type": "Other", "normalized_text": "myeloma"}, {"start": 286, "end": 293, "probability": 0.6234, "type": "Other", "normalized_text": "lymphoma"}, {"start": 371, "end": 377, "probability": 0.8417, "type": "Other", "normalized_text": "Twitter"}], "mentions": [{"start": 0, "end": 14, "username": "MichaelJSlade", "id": "626650397"}, {"start": 15, "end": 29, "username": "CyclingDoctor", "id": "23036480"}, {"start": 30, "end": 42, "username": "LabFehniger", "id": "1198731683199098881"}, {"start": 43, "end": 55, "username": "DiPersioLab", "id": "1349142172415762433"}, {"start": 56, "end": 71, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 72, "end": 81, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 82, "end": 96, "username": "DavidSteensma", "id": "2739065578"}, {"start": 97, "end": 107, "username": "bdermanmd", "id": "872983600416862208"}, {"start": 108, "end": 121, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 122, "end": 132, "username": "VincentRK", "id": "24261916"}, {"start": 133, "end": 143, "username": "myelomaMD", "id": "301568235"}, {"start": 144, "end": 153, "username": "Geoff_Uy", "id": "985139345928736768"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1600642889280798721"}], "id": "1600669885931040768", "text": "@MichaelJSlade @CyclingDoctor @LabFehniger @DiPersioLab @AaronGoodman33 @ManniMD1 @DavidSteensma @bdermanmd @VPrasadMDMPH @VincentRK @myelomaMD @Geoff_Uy Start with plenary sessions, then oral abstracts and Late Breaking Anstracts. Pick diseases your most interested in, first(myeloma, lymphoma etc..) try to start with clinically relevant. Follow the people you like on Twitter, they\u2019ll be tweeting all their favorites", "lang": "en", "author_id": "3025849894", "conversation_id": "1600642889280798721", "edit_history_tweet_ids": ["1600669885931040768"], "created_at": "2022-12-08T01:53:34.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 20, "end": 24, "probability": 0.6247, "type": "Other", "normalized_text": "ASH22"}], "hashtags": [{"start": 19, "end": 25, "tag": "ASH22"}, {"start": 61, "end": 67, "tag": "leusm"}, {"start": 68, "end": 74, "tag": "lymsm"}, {"start": 75, "end": 80, "tag": "mmsm"}, {"start": 81, "end": 87, "tag": "mpnsm"}], "mentions": [{"start": 0, "end": 14, "username": "MichaelJSlade", "id": "626650397"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1600642889280798721"}], "id": "1600659677607591936", "text": "@MichaelJSlade Use #ASH22 and disease specific hashtags - eg #leusm #lymsm #mmsm #mpnsm \u2014 and follow. Few key people in field(s) of interest that curate info", "lang": "en", "author_id": "190337035", "conversation_id": "1600642889280798721", "edit_history_tweet_ids": ["1600659677607591936"], "created_at": "2022-12-08T01:13:00.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 63, "end": 69, "probability": 0.6243, "type": "Other", "normalized_text": "ASH2022"}], "hashtags": [{"start": 62, "end": 70, "tag": "ASH2022"}], "mentions": [{"start": 141, "end": 155, "username": "CyclingDoctor", "id": "23036480"}, {"start": 156, "end": 168, "username": "LabFehniger", "id": "1198731683199098881"}, {"start": 169, "end": 181, "username": "DiPersioLab", "id": "1349142172415762433"}, {"start": 182, "end": 197, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 198, "end": 207, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 208, "end": 222, "username": "DavidSteensma", "id": "2739065578"}, {"start": 223, "end": 233, "username": "bdermanmd", "id": "872983600416862208"}, {"start": 234, "end": 247, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 248, "end": 258, "username": "VincentRK", "id": "24261916"}, {"start": 259, "end": 269, "username": "myelomaMD", "id": "301568235"}, {"start": 270, "end": 279, "username": "Geoff_Uy", "id": "985139345928736768"}]}, "id": "1600642889280798721", "text": "As a trainee who\u2019s overwhelmed by the volume of abstracts for #ASH2022, any advice on filtering/reviewing/scheduling from the senior folks?\n\n@CyclingDoctor @LabFehniger @DiPersioLab @AaronGoodman33 @ManniMD1 @DavidSteensma @bdermanmd @VPrasadMDMPH @VincentRK @myelomaMD @Geoff_Uy", "lang": "en", "author_id": "626650397", "conversation_id": "1600642889280798721", "edit_history_tweet_ids": ["1600642889280798721"], "created_at": "2022-12-08T00:06:17.000Z"}, {"entities": {"annotations": [{"start": 138, "end": 142, "probability": 0.7251, "type": "Other", "normalized_text": "BWHit"}, {"start": 197, "end": 202, "probability": 0.9669, "type": "Place", "normalized_text": "Boston"}, {"start": 276, "end": 284, "probability": 0.9704, "type": "Place", "normalized_text": "Cleveland"}, {"start": 322, "end": 327, "probability": 0.9184, "type": "Place", "normalized_text": "Boston"}], "mentions": [{"start": 0, "end": 16, "username": "RahulBanerjeeMD", "id": "26399236"}, {"start": 17, "end": 31, "username": "MichaelJSlade", "id": "626650397"}, {"start": 32, "end": 39, "username": "INizMD", "id": "1126278189549072385"}, {"start": 40, "end": 54, "username": "DavidSteensma", "id": "2739065578"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1598536730269081601"}], "id": "1598645056436547585", "text": "@RahulBanerjeeMD @MichaelJSlade @INizMD @DavidSteensma Having started my transition from finance to medicine volunteering and rotating at BWHit\u2019s a great place with great people. Other programs in Boston are able to bring diverse candidates in. Hard sell to someone living in Cleveland that it is impossible to recruit to Boston.", "lang": "en", "author_id": "1283867959979630596", "conversation_id": "1598480153872666624", "edit_history_tweet_ids": ["1598645056436547585"], "created_at": "2022-12-02T11:47:37.000Z", "in_reply_to_user_id": "26399236"}, {"entities": {"annotations": [{"start": 257, "end": 262, "probability": 0.9633, "type": "Place", "normalized_text": "Boston"}], "mentions": [{"start": 0, "end": 7, "username": "INizMD", "id": "1126278189549072385"}, {"start": 8, "end": 22, "username": "DavidSteensma", "id": "2739065578"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1598502108285779970"}], "id": "1598515663509028865", "text": "@INizMD @DavidSteensma Agreed - I just remember being how impressed I were by them naming this as an area of improvement for them instead of sweeping it under the carpet.\n\nAlways a tough situation since every applicant is unique - some might have stayed in Boston for family / personal reasons too!", "lang": "en", "author_id": "26399236", "conversation_id": "1598480153872666624", "edit_history_tweet_ids": ["1598515663509028865"], "created_at": "2022-12-02T03:13:27.000Z", "in_reply_to_user_id": "1126278189549072385"}, {"referenced_tweets": [{"type": "replied_to", "id": "1598493476945121287"}], "id": "1598493681853546497", "text": "@JineshGheeya Agreed. I cannot stand the spin.", "lang": "en", "author_id": "18821994", "conversation_id": "1598458399670280194", "edit_history_tweet_ids": ["1598493681853546497"], "created_at": "2022-12-02T01:46:06.000Z", "entities": {"mentions": [{"start": 0, "end": 13, "username": "JineshGheeya", "id": "1561772329138626560"}]}, "in_reply_to_user_id": "1561772329138626560"}, {"entities": {"annotations": [{"start": 140, "end": 142, "probability": 0.4484, "type": "Other", "normalized_text": "TCR"}, {"start": 147, "end": 149, "probability": 0.3929, "type": "Other", "normalized_text": "PCR"}, {"start": 177, "end": 186, "probability": 0.4507, "type": "Other", "normalized_text": "belantamab"}, {"start": 227, "end": 230, "probability": 0.3853, "type": "Other", "normalized_text": "HDCy"}, {"start": 235, "end": 238, "probability": 0.4408, "type": "Other", "normalized_text": "DCEP"}], "mentions": [{"start": 0, "end": 10, "username": "VincentRK", "id": "24261916"}, {"start": 11, "end": 20, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 21, "end": 27, "username": "GSKUS", "id": "22623663"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1595228631835500545"}], "id": "1595451503623430146", "text": "@VincentRK @ManniMD1 @GSKUS If the goal is to get agents that work when we're running out of options, would the right approach be to enroll TCR or PCR patients for single agent belantamab vs. physician's choice therapy? (Often HDCy or DCEP at our center).", "lang": "en", "author_id": "626650397", "conversation_id": "1595220125631881217", "edit_history_tweet_ids": ["1595451503623430146"], "created_at": "2022-11-23T16:17:35.000Z", "in_reply_to_user_id": "24261916"}, {"entities": {"annotations": [{"start": 26, "end": 36, "probability": 0.6235, "type": "Other", "normalized_text": "carfilzomib"}, {"start": 167, "end": 179, "probability": 0.9678, "type": "Person", "normalized_text": "Keith Stewart"}, {"start": 200, "end": 203, "probability": 0.6065, "type": "Other", "normalized_text": "ECOG"}, {"start": 258, "end": 262, "probability": 0.4958, "type": "Other", "normalized_text": "Amgen"}], "mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 10, "end": 16, "username": "GSKUS", "id": "22623663"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1595227570320166912"}], "id": "1595228631835500545", "text": "@ManniMD1 @GSKUS 10/ when carfilzomib was being developed I was one of the few who warned onyx that FOCUS trial was risky and cytoxan would be hard to beat. The trial Keith Stewart and I designed for ECOG was thankfully adopted as another pivotal trial when Amgen took over. That was ASPIRE.", "lang": "en", "author_id": "24261916", "conversation_id": "1595220125631881217", "edit_history_tweet_ids": ["1595228631835500545"], "created_at": "2022-11-23T01:31:58.000Z", "in_reply_to_user_id": "24261916"}, {"entities": {"annotations": [{"start": 156, "end": 162, "probability": 0.3853, "type": "Other", "normalized_text": "myeloma"}, {"start": 198, "end": 200, "probability": 0.4647, "type": "Other", "normalized_text": "VMP"}, {"start": 203, "end": 214, "probability": 0.4137, "type": "Other", "normalized_text": "chlorambucil"}, {"start": 220, "end": 222, "probability": 0.5272, "type": "Other", "normalized_text": "CLL"}, {"start": 246, "end": 248, "probability": 0.9212, "type": "Organization", "normalized_text": "NHL"}], "hashtags": [{"start": 27, "end": 36, "tag": "thankful"}]}, "id": "1595425108964900867", "text": "Among the many things I am #thankful for: recent progress in hematologic malignancies. When I started my career - not that long ago! - standard therapy for myeloma was melphalan &amp; prednisone or VMP, chlorambucil for CLL, CHOP (without R) for NHL, epoetin &amp; transfusions for MDS./1", "lang": "en", "author_id": "2739065578", "conversation_id": "1595425108964900867", "edit_history_tweet_ids": ["1595425108964900867"], "created_at": "2022-11-23T14:32:42.000Z"}, {"entities": {"annotations": [{"start": 3, "end": 5, "probability": 0.8668, "type": "Organization", "normalized_text": "FDA"}, {"start": 26, "end": 27, "probability": 0.4528, "type": "Other", "normalized_text": "-T"}, {"start": 37, "end": 40, "probability": 0.4832, "type": "Other", "normalized_text": "BiTE"}, {"start": 52, "end": 55, "probability": 0.4616, "type": "Organization", "normalized_text": "BCMA"}, {"start": 140, "end": 144, "probability": 0.5486, "type": "Other", "normalized_text": "BiTEs"}, {"start": 156, "end": 159, "probability": 0.4515, "type": "Other", "normalized_text": "BCMA"}, {"start": 162, "end": 167, "probability": 0.7482, "type": "Other", "normalized_text": "GPRC5D"}, {"start": 173, "end": 177, "probability": 0.7871, "type": "Other", "normalized_text": "FcRH5"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1595193540493152257"}], "id": "1595193541982134273", "text": "2) FDA Approval of two CAR-T and one BiTE targeting BCMA: not only these treatments were effective, but there was a concern of other future BiTEs targeting BCMA, GPRC5D and FcRH5 which are showing promising results, making it difficult to compete in the future", "lang": "en", "author_id": "1026947037080772610", "conversation_id": "1595193537674575872", "edit_history_tweet_ids": ["1595193541982134273"], "created_at": "2022-11-22T23:12:32.000Z", "in_reply_to_user_id": "1026947037080772610"}, {"entities": {"annotations": [{"start": 159, "end": 163, "probability": 0.7809, "type": "Other", "normalized_text": " of N"}, {"start": 243, "end": 246, "probability": 0.6684, "type": "Other", "normalized_text": "in #"}], "hashtags": [{"start": 246, "end": 251, "tag": "MMsm"}], "urls": [{"start": 283, "end": 306, "url": "https://t.co/ImGti2lSNf", "expanded_url": "https://twitter.com/RahulBanerjeeMD/status/1594715525963485184/photo/1", "display_url": "pic.twitter.com/ImGti2lSNf", "media_key": "3_1594715522364768257"}]}, "id": "1594715525963485184", "text": "We need an onc boards prep book where each q is written by \ud83d\udc68\u200d\u2695\ufe0f\ud83d\udc69\u200d\u2695\ufe0f who don\u2019t treat that cancer\u2026\n\nI.e., I\u2019m not sure it\u2019s \u201cessential\u201d to know exact frequencies of NSCLC mutations.\n\nBut I\u2019d be just as guilty of saying that gain(1q) vs amp (1q) in #MMsm absolutely essential to know \ud83e\udd23 https://t.co/ImGti2lSNf", "lang": "en", "author_id": "26399236", "conversation_id": "1594715525963485184", "edit_history_tweet_ids": ["1594715525963485184"], "created_at": "2022-11-21T15:33:04.000Z"}, {"referenced_tweets": [{"type": "replied_to", "id": "1594474449897668610"}], "id": "1594474451252412419", "text": "Starting doses of oral small molecules (unless compared meaningfully in a clinical trial)", "lang": "en", "author_id": "626650397", "conversation_id": "1594474444805767169", "edit_history_tweet_ids": ["1594474451252412419"], "created_at": "2022-11-20T23:35:07.000Z", "in_reply_to_user_id": "626650397"}, {"referenced_tweets": [{"type": "replied_to", "id": "1594474448350244864"}], "id": "1594474449897668610", "text": "Response rates from trials that are of \"historical interest\"", "lang": "en", "author_id": "626650397", "conversation_id": "1594474444805767169", "edit_history_tweet_ids": ["1594474449897668610"], "created_at": "2022-11-20T23:35:07.000Z", "in_reply_to_user_id": "626650397"}, {"referenced_tweets": [{"type": "replied_to", "id": "1594474446655717376"}], "id": "1594474448350244864", "text": "Any syndrome defined by a triad", "lang": "en", "author_id": "626650397", "conversation_id": "1594474444805767169", "edit_history_tweet_ids": ["1594474448350244864"], "created_at": "2022-11-20T23:35:07.000Z", "in_reply_to_user_id": "626650397"}, {"referenced_tweets": [{"type": "replied_to", "id": "1594474444805767169"}], "id": "1594474446655717376", "text": "Radiation dosing", "lang": "en", "author_id": "626650397", "conversation_id": "1594474444805767169", "edit_history_tweet_ids": ["1594474446655717376"], "created_at": "2022-11-20T23:35:06.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 37, "end": 50, "probability": 0.7665, "type": "Other", "normalized_text": "OncologyBoards"}], "hashtags": [{"start": 36, "end": 51, "tag": "OncologyBoards"}]}, "id": "1594474444805767169", "text": "Things I'm refusing to memorize for #OncologyBoards: a (running) list", "lang": "en", "author_id": "626650397", "conversation_id": "1594474444805767169", "edit_history_tweet_ids": ["1594474444805767169"], "created_at": "2022-11-20T23:35:06.000Z"}, {"entities": {"annotations": [{"start": 49, "end": 53, "probability": 0.7438, "type": "Other", "normalized_text": "CAR-T"}, {"start": 145, "end": 156, "probability": 0.5224, "type": "Person", "normalized_text": "sipoleucel-T"}], "mentions": [{"start": 0, "end": 14, "username": "MichaelJSlade", "id": "626650397"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1592942968209408000"}], "id": "1592990088082100224", "text": "@MichaelJSlade Totally agreed - especially since CAR-T has been commercially available for 5 years! Instead we\u2019ll still be asked questions about sipoleucel-T as the \u201cnew\u201d kid on the block \ud83d\ude44", "lang": "en", "author_id": "26399236", "conversation_id": "1592942968209408000", "edit_history_tweet_ids": ["1592990088082100224"], "created_at": "2022-11-16T21:16:47.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 102, "end": 106, "probability": 0.7326, "type": "Other", "normalized_text": "ASH22"}], "hashtags": [{"start": 101, "end": 107, "tag": "ASH22"}], "urls": [{"start": 279, "end": 302, "url": "https://t.co/HzADLnAJmc", "expanded_url": "https://twitter.com/ManniMD1/status/1590440085656580096", "display_url": "twitter.com/ManniMD1/statu\u2026"}], "mentions": [{"start": 255, "end": 263, "username": "iStopMM", "id": "844232399319941122"}, {"start": 264, "end": 278, "username": "sykristinsson", "id": "3078258341"}]}, "referenced_tweets": [{"type": "quoted", "id": "1590440085656580096"}], "id": "1592885241953554432", "text": "Although this study is only a poster (worthy of oral!), it is one of the most impactful abstracts at #ASH22, with impacts far beyond even the field of hematology.\n\nI intend to present this study to rheumatologists soon, and we all should share the word!\n\n@iStopMM @sykristinsson https://t.co/HzADLnAJmc", "lang": "en", "author_id": "1269642863924609025", "conversation_id": "1592885241953554432", "edit_history_tweet_ids": ["1592885241953554432"], "created_at": "2022-11-16T14:20:10.000Z"}, {"entities": {"annotations": [{"start": 39, "end": 44, "probability": 0.5669, "type": "Other", "normalized_text": "cancer"}, {"start": 75, "end": 80, "probability": 0.7403, "type": "Other", "normalized_text": "cancer"}]}, "id": "1592793042528120835", "text": "You tell me to try a certain diet with cancer patients?\nForgive me but the cancer patients I have seen would be happy if they could taste and eat something normal without pain or the urge to vomit. \nThat's their problem, that's their life!", "lang": "en", "author_id": "1054759355512438786", "conversation_id": "1592793042528120835", "edit_history_tweet_ids": ["1592793042528120835"], "created_at": "2022-11-16T08:13:48.000Z"}, {"id": "1592942968209408000", "entities": {"urls": [{"start": 24, "end": 47, "url": "https://t.co/FjT0MK4Xuv", "expanded_url": "https://twitter.com/MichaelJSlade/status/1592942968209408000/photo/1", "display_url": "pic.twitter.com/FjT0MK4Xuv", "media_key": "3_1592942525232431105"}]}, "text": "Well, this is crushing: https://t.co/FjT0MK4Xuv", "lang": "en", "author_id": "626650397", "conversation_id": "1592942968209408000", "edit_history_tweet_ids": ["1592942968209408000"], "created_at": "2022-11-16T18:09:33.000Z"}, {"id": "1587997743255093250", "text": "Over time I\u2019ve tweeted a lot about evidence-based medicine. But oncologists are often in situations with little or no evidence to guide them.\n\nIn these situations we go to \u201cfirst principles\u201d.  But what are the first principles? Here\u2019s a thread outlining those I think are key.", "lang": "en", "author_id": "1160789125", "conversation_id": "1587997743255093250", "edit_history_tweet_ids": ["1587997743255093250"], "created_at": "2022-11-03T02:39:00.000Z"}, {"referenced_tweets": [{"type": "quoted", "id": "1587212054699483136"}], "id": "1587220437242724352", "entities": {"urls": [{"start": 85, "end": 108, "url": "https://t.co/m08XBNDy7C", "expanded_url": "https://twitter.com/CloneTracker/status/1587212054699483136", "display_url": "twitter.com/CloneTracker/s\u2026"}], "mentions": [{"start": 0, "end": 12, "username": "DiPersioLab", "id": "1349142172415762433"}, {"start": 13, "end": 26, "username": "KellyLBolton", "id": "1108468287036407808"}, {"start": 28, "end": 39, "username": "dgermain21", "id": "18821994"}, {"start": 40, "end": 47, "username": "mpndoc", "id": "2930528191"}, {"start": 48, "end": 60, "username": "LabFehniger", "id": "1198731683199098881"}, {"start": 61, "end": 75, "username": "MichaelJSlade", "id": "626650397"}, {"start": 76, "end": 84, "username": "koetjen", "id": "31625079"}]}, "text": "@DiPersioLab @KellyLBolton  @dgermain21 @mpndoc @LabFehniger @MichaelJSlade @koetjen https://t.co/m08XBNDy7C", "lang": "qam", "author_id": "23036480", "conversation_id": "1587220437242724352", "edit_history_tweet_ids": ["1587220437242724352"], "created_at": "2022-10-31T23:10:16.000Z", "in_reply_to_user_id": "1349142172415762433"}, {"entities": {"annotations": [{"start": 87, "end": 90, "probability": 0.3752, "type": "Organization", "normalized_text": "REMS"}, {"start": 140, "end": 141, "probability": 0.9687, "type": "Place", "normalized_text": "US"}, {"start": 153, "end": 156, "probability": 0.4251, "type": "Organization", "normalized_text": "REMS"}], "mentions": [{"start": 0, "end": 11, "username": "amarkelkar", "id": "16273048"}, {"start": 12, "end": 24, "username": "Eddie_Cliff", "id": "74081884"}, {"start": 25, "end": 37, "username": "HadidiSamer", "id": "774267564"}, {"start": 38, "end": 47, "username": "JCO_ASCO", "id": "2395900849"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1586721662640263169"}], "id": "1586726824943693824", "text": "@amarkelkar @Eddie_Cliff @HadidiSamer @JCO_ASCO This is of course the principle behind REMS programs for toci and hospital resources in the US, but even REMS would assume that transfusions were readily available!", "lang": "en", "author_id": "26399236", "conversation_id": "1586690053060890625", "edit_history_tweet_ids": ["1586726824943693824"], "created_at": "2022-10-30T14:28:49.000Z", "in_reply_to_user_id": "16273048"}, {"referenced_tweets": [{"type": "replied_to", "id": "1586697394732892160"}], "id": "1586701066145505283", "text": "*Rather transplant vs transplant after relapse, as all could receive a graft later.", "lang": "en", "author_id": "1039939970415218688", "conversation_id": "1586697394732892160", "edit_history_tweet_ids": ["1586701066145505283"], "created_at": "2022-10-30T12:46:28.000Z", "in_reply_to_user_id": "1039939970415218688"}, {"referenced_tweets": [{"type": "replied_to", "id": "1586451422660694016"}], "id": "1586491319035531264", "text": "@MichaelJSlade @simonbchen Or: they\u2019re unaware of the ridiculous levels of endogeneity in those studies.", "lang": "en", "author_id": "3206254672", "conversation_id": "1586406414293106690", "edit_history_tweet_ids": ["1586491319035531264"], "created_at": "2022-10-29T22:53:00.000Z", "entities": {"mentions": [{"start": 0, "end": 14, "username": "MichaelJSlade", "id": "626650397"}, {"start": 15, "end": 26, "username": "simonbchen", "id": "919588789827203072"}]}, "in_reply_to_user_id": "626650397"}, {"referenced_tweets": [{"type": "replied_to", "id": "1586406414293106690"}], "id": "1586451025434927104", "text": "@simonbchen I think a lot of folks on the left are familiar with the data showing that households with guns are much, much more likely to have a firearm fatality in a member of the household than defend against an external attack. Political violence is another issue, admittedly.", "lang": "en", "author_id": "626650397", "conversation_id": "1586406414293106690", "edit_history_tweet_ids": ["1586451025434927104"], "created_at": "2022-10-29T20:12:53.000Z", "entities": {"mentions": [{"start": 0, "end": 11, "username": "simonbchen", "id": "919588789827203072"}]}, "in_reply_to_user_id": "919588789827203072"}, {"entities": {"annotations": [{"start": 41, "end": 52, "probability": 0.9649, "type": "Person", "normalized_text": "Nancy Pelosi"}]}, "id": "1586406414293106690", "text": "1/ In wake of shocking violent attack on Nancy Pelosi\u2019s husband, I think it\u2019s important for left-wing Americans to become better acquainted with their constitutional rights under 2nd Amendment. It has always made zero sense to me why left-wing Americans have voluntarily disavowed", "lang": "en", "author_id": "919588789827203072", "conversation_id": "1586406414293106690", "edit_history_tweet_ids": ["1586406414293106690"], "created_at": "2022-10-29T17:15:37.000Z"}, {"entities": {"annotations": [{"start": 171, "end": 173, "probability": 0.543, "type": "Other", "normalized_text": "TKI"}], "mentions": [{"start": 0, "end": 14, "username": "MichaelJSlade", "id": "626650397"}, {"start": 15, "end": 31, "username": "NicholasShortMD", "id": "826584913214316546"}, {"start": 32, "end": 42, "username": "jayastuMD", "id": "1974184626"}, {"start": 43, "end": 55, "username": "LeukemiaJnl", "id": "398801458"}, {"start": 56, "end": 70, "username": "DrHKantarjian", "id": "897448268740923392"}, {"start": 71, "end": 86, "username": "MDAndersonNews", "id": "14062554"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1586428896580206592"}], "id": "1586430284441870336", "text": "@MichaelJSlade @NicholasShortMD @jayastuMD @LeukemiaJnl @DrHKantarjian @MDAndersonNews Yes nice diagram. I do not not perform allo in all accelerated phases even if prior TKI.", "lang": "en", "author_id": "854692626015993857", "conversation_id": "1586397748924157952", "edit_history_tweet_ids": ["1586430284441870336"], "created_at": "2022-10-29T18:50:28.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 145, "end": 147, "probability": 0.5171, "type": "Organization", "normalized_text": "CML"}], "hashtags": [{"start": 144, "end": 148, "tag": "CML"}], "urls": [{"start": 252, "end": 275, "url": "https://t.co/CC1C4AgNw1", "expanded_url": "https://tinyurl.com/bdfreua2", "display_url": "tinyurl.com/bdfreua2", "status": 200, "unwound_url": "https://www.nature.com/articles/s41375-022-01736-5?error=cookies_not_supported&code=5ce5384f-988b-4a76-9f1e-4bf87e4703ed"}, {"start": 276, "end": 299, "url": "https://t.co/f8SFyHKHcT", "expanded_url": "https://twitter.com/NicholasShortMD/status/1586397748924157952/photo/1", "display_url": "pic.twitter.com/f8SFyHKHcT", "media_key": "3_1586396692928143361"}], "mentions": [{"start": 43, "end": 53, "username": "jayastuMD", "id": "1974184626"}, {"start": 65, "end": 77, "username": "LeukemiaJnl", "id": "398801458"}]}, "id": "1586397748924157952", "text": "An outstanding and comprehensive review by @jayastuMD out now in @LeukemiaJnl on the pathogenesis and management of accelerated and blast phase #CML. I honestly think he has written the most definitive review on the topic to date! \n\ud83d\udc49Check it out here: https://t.co/CC1C4AgNw1 https://t.co/f8SFyHKHcT", "lang": "en", "author_id": "826584913214316546", "conversation_id": "1586397748924157952", "edit_history_tweet_ids": ["1586397748924157952"], "created_at": "2022-10-29T16:41:11.000Z"}, {"id": "1586403917365010432", "text": "Advice I could have used when starting fellowship\u2026\n \nNo matter how stupid or useless you think the consult is be nice and do it.\n\nIf they are calling you then they need help regardless of the question just do it and be helpful!", "lang": "en", "author_id": "854692626015993857", "conversation_id": "1586403917365010432", "edit_history_tweet_ids": ["1586403917365010432"], "created_at": "2022-10-29T17:05:42.000Z"}, {"entities": {"annotations": [{"start": 27, "end": 29, "probability": 0.9194, "type": "Organization", "normalized_text": "FDA"}, {"start": 73, "end": 86, "probability": 0.4272, "type": "Other", "normalized_text": "thyroid cancer"}]}, "id": "1586396680882212868", "text": "Board factoid #1:\n\nWe have FDA approved medical treatment for anaplastic thyroid cancer! What mutation is targeted and what agents are used?", "lang": "en", "author_id": "626650397", "conversation_id": "1586396680882212868", "edit_history_tweet_ids": ["1586396680882212868"], "created_at": "2022-10-29T16:36:57.000Z"}, {"id": "1586393838217633792", "text": "Studying for the boards is awesome. It's an opportunity to be reminded of subtleties re: agents or diseases you don't see much in your area of focus. \n\nFor the next *checks calendar* four weeks, I'll be posting boards factoids that I never knew (or forgot).\n\nGood luck studying!", "lang": "en", "author_id": "626650397", "conversation_id": "1586393838217633792", "edit_history_tweet_ids": ["1586393838217633792"], "created_at": "2022-10-29T16:25:39.000Z"}, {"entities": {"annotations": [{"start": 118, "end": 124, "probability": 0.5709, "type": "Other", "normalized_text": "myeloma"}, {"start": 128, "end": 131, "probability": 0.3956, "type": "Other", "normalized_text": "mmsm"}, {"start": 134, "end": 138, "probability": 0.3527, "type": "Organization", "normalized_text": "bmtsm"}, {"start": 148, "end": 152, "probability": 0.2889, "type": "Other", "normalized_text": "leusm"}], "hashtags": [{"start": 117, "end": 125, "tag": "myeloma"}, {"start": 127, "end": 132, "tag": "mmsm"}, {"start": 133, "end": 139, "tag": "bmtsm"}, {"start": 140, "end": 146, "tag": "lymsm"}, {"start": 147, "end": 153, "tag": "leusm"}], "urls": [{"start": 155, "end": 178, "url": "https://t.co/E5f00Qdxj4", "expanded_url": "https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(22)00289-7/fulltext", "display_url": "thelancet.com/journals/lanha\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1600068791848747008/n3e8x4KV?format=jpg&name=orig", "width": 447, "height": 648}, {"url": "https://pbs.twimg.com/news_img/1600068791848747008/n3e8x4KV?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis", "description": "Based on the current data, lenalidomide-induced SPM seem to occur exclusively in patients with multiple myeloma. Thus, lenalidomide can be used for other indications without the major concern of a therapy-related neoplasm. In the multiple myeloma setting, lenalidomide is an effective drug, but patients should be monitored both for haematological and solid tumour SPM. This monitoring includes patients that have not received autologous haematopoietic stem-cell transplantation. Further investigations are needed to improve understanding on why lenalidomide only promotes SPM in patients with multiple myeloma.", "unwound_url": "https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(22)00289-7/fulltext"}]}, "id": "1585937001928622080", "text": "This meta-analysis finds that lenalidomide-associated second primary malignancies occur exclusively in patients with #myeloma.\n#mmsm #bmtsm #lymsm #leusm\n\nhttps://t.co/E5f00Qdxj4", "lang": "en", "author_id": "23036480", "conversation_id": "1585937001928622080", "edit_history_tweet_ids": ["1585937001928622080"], "created_at": "2022-10-28T10:10:21.000Z"}, {"referenced_tweets": [{"type": "replied_to", "id": "1586133210832211969"}], "id": "1586133213147037696", "text": "Worth noting the senior author on this manuscript is an @AstellasUS  employee and paid medical writers were involved in drafting. Maybe this is why the discussion reads like a press release. \n\nOverall: good study, moves field forward, but discussion leaves bad taste.  \n\n/end", "lang": "en", "author_id": "626650397", "conversation_id": "1586133202787135488", "edit_history_tweet_ids": ["1586133213147037696"], "created_at": "2022-10-28T23:10:01.000Z", "entities": {"mentions": [{"start": 56, "end": 67, "username": "AstellasUS", "id": "27900939"}]}, "in_reply_to_user_id": "626650397"}, {"referenced_tweets": [{"type": "replied_to", "id": "1586133208621404160"}], "id": "1586133210832211969", "text": "I wish editorial control was a little tighter for study design-related fallacies. If someone misrepresents prior literature or uses the wrong statistical approach, the paper is not accepted until it's fixed. Can't we do the same here?\n\n5/n", "lang": "en", "author_id": "626650397", "conversation_id": "1586133202787135488", "edit_history_tweet_ids": ["1586133210832211969"], "created_at": "2022-10-28T23:10:01.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 114, "end": 116, "probability": 0.4567, "type": "Other", "normalized_text": "RCT"}, {"start": 205, "end": 208, "probability": 0.8045, "type": "Other", "normalized_text": "FLT3"}, {"start": 230, "end": 233, "probability": 0.6334, "type": "Other", "normalized_text": "RCTs"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1586133206822457344"}], "id": "1586133208621404160", "text": "It went on to blame (appropriate) subsequent therapy  and a (NS) imbalance in baseline demographic factors (in an RCT) for lack of OS benefit. It also noted a sicker (randomized) cohort and enrichment for FLT3 mutations vs. other RCTs in space (sigh) .  \n\n4/n", "lang": "en", "author_id": "626650397", "conversation_id": "1586133202787135488", "edit_history_tweet_ids": ["1586133208621404160"], "created_at": "2022-10-28T23:10:00.000Z", "in_reply_to_user_id": "626650397"}, {"referenced_tweets": [{"type": "replied_to", "id": "1586133204947423243"}], "id": "1586133206822457344", "text": "Second, complaints:\n\nHonestly, mostly the discussion (this will go on awhile). The first paragraph was bad. It admitted the study was negative, but went on to tout a 1 month OS diff (NS) overall, 6.3 month OS diff in high allelic ratio (NS, not power, not pre-specified).  \n\n3/n", "lang": "en", "author_id": "626650397", "conversation_id": "1586133202787135488", "edit_history_tweet_ids": ["1586133206822457344"], "created_at": "2022-10-28T23:10:00.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 18, "end": 21, "probability": 0.4346, "type": "Other", "normalized_text": "RCTs"}, {"start": 180, "end": 182, "probability": 0.8774, "type": "Place", "normalized_text": "USA"}, {"start": 246, "end": 251, "probability": 0.9501, "type": "Place", "normalized_text": "Canada"}, {"start": 253, "end": 258, "probability": 0.9539, "type": "Place", "normalized_text": "Europe"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1586133202787135488"}], "id": "1586133204947423243", "text": "First, kudos:\n\n1) RCTs are hard. Congrats to authors, despite a negative study\n2) Huge area of need. Older patients aren't studied enough. Median age 75+, ~45% ECOG 2. \n3) For non-USA pop, aza control arm = okay. Last enrolled 8/2020, pre-Ven in Canada/Europe\n4) OS endpoint!\n\n2/n", "lang": "en", "author_id": "626650397", "conversation_id": "1586133202787135488", "edit_history_tweet_ids": ["1586133204947423243"], "created_at": "2022-10-28T23:09:59.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 21, "end": 31, "probability": 0.6475, "type": "Other", "normalized_text": "azacytidine"}, {"start": 53, "end": 56, "probability": 0.6584, "type": "Other", "normalized_text": "FLT3"}, {"start": 157, "end": 159, "probability": 0.4162, "type": "Other", "normalized_text": "AML"}, {"start": 201, "end": 204, "probability": 0.8043, "type": "Other", "normalized_text": "FLT3"}], "urls": [{"start": 243, "end": 266, "url": "https://t.co/vB56Nzeoy6", "expanded_url": "https://tinyurl.com/yc35sthb", "display_url": "tinyurl.com/yc35sthb", "status": 200, "unwound_url": "https://ashpublications.org/blood/article/140/17/1845/486088/Phase-3-trial-of-gilteritinib-plus-azacitidine-vs?utm_source=&utm_medium=&utm_campaign=twib_140_17%20&utm_source=sfmc&utm_medium=email&utm_campaign=TWIB_140_17&utm_term=Link+Text+%c2%bb&utm_id=201943&sfmc_id=19361364"}], "mentions": [{"start": 103, "end": 116, "username": "BloodJournal", "id": "3407436940"}]}, "id": "1586133202787135488", "text": "The LACEWING phase 3 azacytidine +/- gilteritinib in FLT3-mut AML not eligible for intensive chemo (in @BloodJournal) shows, again, that targeted therapy in AML is hard (and targeting late events like FLT3 might not be the right approach).  \n\nhttps://t.co/vB56Nzeoy6\n\n1/n", "lang": "en", "author_id": "626650397", "conversation_id": "1586133202787135488", "edit_history_tweet_ids": ["1586133202787135488"], "created_at": "2022-10-28T23:09:59.000Z"}, {"entities": {"annotations": [{"start": 34, "end": 36, "probability": 0.311, "type": "Other", "normalized_text": "IIT"}, {"start": 77, "end": 78, "probability": 0.3941, "type": "Place", "normalized_text": "FL"}], "urls": [{"start": 81, "end": 104, "url": "https://t.co/KztUa9aZYP", "expanded_url": "https://clinicaltrials.gov/ct2/show/NCT05410418", "display_url": "clinicaltrials.gov/ct2/show/NCT05\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1586090754291781633/VWTHcmUA?format=png&name=orig", "width": 720, "height": 720}, {"url": "https://pbs.twimg.com/news_img/1586090754291781633/VWTHcmUA?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma - Full Text View - ClinicalTrials.gov", "description": "Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma - Full Text View.", "unwound_url": "https://clinicaltrials.gov/ct2/show/NCT05410418"}], "mentions": [{"start": 202, "end": 218, "username": "nancybartlettMD", "id": "1172582075913986048"}, {"start": 223, "end": 235, "username": "LabFehniger", "id": "1198731683199098881"}, {"start": 250, "end": 264, "username": "SitemanCenter", "id": "89517086"}]}, "id": "1586090748067385346", "text": "Excited to announce my fellowship IIT is officially open: mosun + pola in 1L FL\n\nhttps://t.co/KztUa9aZYP.\n\nAn incredible experience thus far, and journey is just beginning. Massive gratitude to mentors @nancybartlettMD and @LabFehniger, plus amazing @SitemanCenter staff.", "lang": "en", "author_id": "18821994", "conversation_id": "1586090748067385346", "edit_history_tweet_ids": ["1586090748067385346"], "created_at": "2022-10-28T20:21:17.000Z"}, {"entities": {"annotations": [{"start": 13, "end": 22, "probability": 0.7274, "type": "Person", "normalized_text": "Paul Hinds"}, {"start": 47, "end": 63, "probability": 0.6513, "type": "Organization", "normalized_text": "United Healthcare"}, {"start": 75, "end": 79, "probability": 0.643, "type": "Other", "normalized_text": "COBRA"}, {"start": 146, "end": 157, "probability": 0.7297, "type": "Other", "normalized_text": "Lupron Depot"}], "urls": [{"start": 203, "end": 226, "url": "https://t.co/kJkwGvxOrs", "expanded_url": "https://www.npr.org/sections/health-shots/2022/10/26/1131130875/it-cost-38-398-for-a-single-shot-of-a-very-old-cancer-drug", "display_url": "npr.org/sections/healt\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1592295668726771712/Xhhkf-LP?format=jpg&name=orig", "width": 1400, "height": 787}, {"url": "https://pbs.twimg.com/news_img/1592295668726771712/Xhhkf-LP?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "It cost $38,398 for a single shot of a very old cancer drug", "description": "Lupron, a drug patented half a century ago, treats advanced prostate cancer. It costs a few hundred dollars in the U.K. \u2014 so why are U.S. hospitals charging so much more to administer it?", "unwound_url": "https://www.npr.org/sections/health-shots/2022/10/26/1131130875/it-cost-38-398-for-a-single-shot-of-a-very-old-cancer-drug"}]}, "id": "1585613437400383489", "text": "The Patient: Paul Hinds, now 60, is covered by United Healthcare through a COBRA plan from his former employer.\n\nMedical Service: Two three-month Lupron Depot injections for metastatic prostate cancer.\n\nhttps://t.co/kJkwGvxOrs", "lang": "en", "author_id": "1017068031166599169", "conversation_id": "1585613437400383489", "edit_history_tweet_ids": ["1585613437400383489"], "created_at": "2022-10-27T12:44:37.000Z"}, {"entities": {"annotations": [{"start": 1, "end": 14, "probability": 0.4657, "type": "Other", "normalized_text": "WUDeptMedicine"}, {"start": 45, "end": 64, "probability": 0.449, "type": "Other", "normalized_text": "Division of Oncology"}, {"start": 96, "end": 110, "probability": 0.4409, "type": "Person", "normalized_text": "Victoria Fraser"}, {"start": 124, "end": 145, "probability": 0.6792, "type": "Organization", "normalized_text": "Department of Medicine"}], "hashtags": [{"start": 0, "end": 15, "tag": "WUDeptMedicine"}], "urls": [{"start": 153, "end": 176, "url": "https://t.co/oJeXoLjTTL", "expanded_url": "http://ow.ly/4uCQ50Lm4vG", "display_url": "ow.ly/4uCQ50Lm4vG", "images": [{"url": "https://pbs.twimg.com/news_img/1585363460656971776/6ccezM68?format=jpg&name=orig", "width": 1200, "height": 800}, {"url": "https://pbs.twimg.com/news_img/1585363460656971776/6ccezM68?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Leadership Announcement \u2013 Division Chief of the Division of Oncology and Deputy Director of Siteman Cancer Center - John T. Milliken Department of Medicine", "description": "It is my pleasure to announce that Daniel\u00a0C. Link, MD, has been named the new Chief of the Division of Oncology in the Department of Medicine and Deputy Director of the Siteman Cancer Center (SCC) effective December\u00a01, 2022. Dr.\u00a0Link is the Alan\u00a0A. and Edith\u00a0L. Wolff Distinguished Professor of Medicine in the Division of Oncology in [\u2026]", "unwound_url": "https://internalmedicine.wustl.edu/leadership-announcement-division-chief-of-the-division-of-oncology-and-deputy-director-of-siteman-cancer-center/"}, {"start": 188, "end": 211, "url": "https://t.co/YkxbONFZR8", "expanded_url": "https://twitter.com/WUDeptMedicine/status/1585363441610522625/photo/1", "display_url": "pic.twitter.com/YkxbONFZR8", "media_key": "3_1585363439395999748"}], "mentions": [{"start": 178, "end": 187, "username": "WUSTLmed", "id": "27779882"}]}, "id": "1585363441610522625", "text": "#WUDeptMedicine announces new leadership for Division of Oncology. Read full announcement from  Victoria Fraser, MD, Chair, Department of Medicine here: https://t.co/oJeXoLjTTL\n\n@WUSTLmed https://t.co/YkxbONFZR8", "lang": "en", "author_id": "1105452868771946497", "conversation_id": "1585363441610522625", "edit_history_tweet_ids": ["1585363441610522625"], "created_at": "2022-10-26T20:11:13.000Z"}, {"entities": {"annotations": [{"start": 110, "end": 112, "probability": 0.6363, "type": "Other", "normalized_text": "PFS"}], "mentions": [{"start": 0, "end": 14, "username": "MichaelJSlade", "id": "626650397"}, {"start": 15, "end": 24, "username": "szusmani", "id": "83911786"}, {"start": 25, "end": 41, "username": "SocietyofHemOnc", "id": "3300834954"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1576222131653734402"}], "id": "1576223837464985601", "text": "@MichaelJSlade @szusmani @SocietyofHemOnc Agree though the difficulty of demonstrating benefit given extended PFS these days will be much harder.", "lang": "en", "author_id": "1081903728", "conversation_id": "1576208128626114560", "edit_history_tweet_ids": ["1576223837464985601"], "created_at": "2022-10-01T14:53:42.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 59, "end": 65, "probability": 0.4899, "type": "Other", "normalized_text": "eat aut"}, {"start": 72, "end": 78, "probability": 0.7864, "type": "Other", "normalized_text": "or #mye"}], "hashtags": [{"start": 75, "end": 83, "tag": "myeloma"}], "urls": [{"start": 104, "end": 127, "url": "https://t.co/j4jJcBQhmX", "expanded_url": "https://twitter.com/drkomanduri/status/1576208128626114560/photo/1", "display_url": "pic.twitter.com/j4jJcBQhmX", "media_key": "3_1576208123093737473"}], "mentions": [{"start": 23, "end": 32, "username": "szusmani", "id": "83911786"}, {"start": 86, "end": 102, "username": "SocietyofHemOnc", "id": "3300834954"}]}, "id": "1576208128626114560", "text": "Nice summary slide by \u2066@szusmani\u2069 on what it will take to beat autoSCT for #myeloma. \u2066@SocietyofHemOnc\u2069 https://t.co/j4jJcBQhmX", "lang": "en", "author_id": "1081903728", "conversation_id": "1576208128626114560", "edit_history_tweet_ids": ["1576208128626114560"], "created_at": "2022-10-01T13:51:17.000Z"}, {"entities": {"annotations": [{"start": 155, "end": 158, "probability": 0.5165, "type": "Other", "normalized_text": "eGFR"}, {"start": 187, "end": 190, "probability": 0.5768, "type": "Other", "normalized_text": "Epic"}], "mentions": [{"start": 0, "end": 14, "username": "MichaelJSlade", "id": "626650397"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1574576681238646785"}], "id": "1574698614395645952", "text": "@MichaelJSlade To be honest, this sounds like an Epic issue. It should be fairly simple to adjust the reference value on a case by case basis based on the eGFR. I am a bit surprised that Epic can't support this", "lang": "en", "author_id": "133109181", "conversation_id": "1574576681238646785", "edit_history_tweet_ids": ["1574698614395645952"], "created_at": "2022-09-27T09:53:00.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 31, "end": 34, "probability": 0.5665, "type": "Other", "normalized_text": "MGUS"}], "urls": [{"start": 178, "end": 201, "url": "https://t.co/xWzjdbrMYw", "expanded_url": "https://rdcu.be/cVw40", "display_url": "rdcu.be/cVw40", "status": 200, "unwound_url": "https://www.nature.com/articles/s41408-022-00732-3.epdf?sharing_token=be_jyr5_H0n0KX4Ae9Tl4tRgN0jAjWel9jnR3ZoTv0OhZ7TA_7WiBKrFOCJxMthJbyzHLTvYped-D9O_r3sEwUciwYize6yB4vNfAdOUgpUowNt8hvVF0HRLK5VyCU63JAo6rUjGdycaq4FC3pxeL8hc33kkWkxAJpLGZAd_nw4%3D&error=cookies_not_supported&code=879af185-f6a8-4c38-a1a9-331b83cc5f68"}, {"start": 284, "end": 307, "url": "https://t.co/jGL2LO9cuw", "expanded_url": "https://twitter.com/sykristinsson/status/1574422541711642625/photo/1", "display_url": "pic.twitter.com/jGL2LO9cuw", "media_key": "3_1574415310794407936"}], "mentions": [{"start": 202, "end": 213, "username": "thorirlong", "id": "3009607268"}]}, "id": "1574422541711642625", "text": "New definition for light chain MGUS! \n\nPractice changing: New ref values for free light chains (FLC), kappa+ lambda in people with kidney dysfunction (GFR&lt;60) just published: https://t.co/xWzjdbrMYw @thorirlong \n\nAvoid unnecessary consultations, bone marrows, and\u2b07\ufe0fpatient anxiety https://t.co/jGL2LO9cuw", "lang": "en", "author_id": "3078258341", "conversation_id": "1574422541711642625", "edit_history_tweet_ids": ["1574422541711642625"], "created_at": "2022-09-26T15:35:59.000Z"}, {"id": "1570551509506727936", "entities": {"hashtags": [{"start": 122, "end": 136, "tag": "sorrynotsorry"}, {"start": 137, "end": 154, "tag": "dadbodlikePujols"}, {"start": 155, "end": 169, "tag": "bigbatsletsgo"}], "urls": [{"start": 280, "end": 303, "url": "https://t.co/inqTqZ5Nu2", "expanded_url": "https://twitter.com/mpndoc/status/1570551509506727936/photo/1", "display_url": "pic.twitter.com/inqTqZ5Nu2", "media_key": "3_1570550913881853952"}], "mentions": [{"start": 171, "end": 187, "username": "WUHemeOncFellow", "id": "1541500129399775234"}, {"start": 188, "end": 198, "username": "WashUHeme", "id": "1387867182609178624"}, {"start": 199, "end": 208, "username": "WashUDPS", "id": "1276507179575541761"}, {"start": 209, "end": 224, "username": "WUDeptMedicine", "id": "1105452868771946497"}, {"start": 225, "end": 236, "username": "dgermain21", "id": "18821994"}, {"start": 237, "end": 251, "username": "MichaelJSlade", "id": "626650397"}, {"start": 252, "end": 263, "username": "RPachynski", "id": "1179604816198275072"}, {"start": 264, "end": 279, "username": "SanaSaifUrRehm", "id": "1533874462503972865"}]}, "text": "\u26be\ufe0fI say this with all due respect but for the sake of transparency I must disclose that the faculty are going to dominate #sorrynotsorry #dadbodlikePujols #bigbatsletsgo \ud83d\udcaa@WUHemeOncFellow @WashUHeme @WashUDPS @WUDeptMedicine @dgermain21 @MichaelJSlade @RPachynski @SanaSaifUrRehm https://t.co/inqTqZ5Nu2", "lang": "en", "author_id": "2930528191", "conversation_id": "1570551509506727936", "edit_history_tweet_ids": ["1570551509506727936"], "created_at": "2022-09-15T23:13:53.000Z"}, {"id": "1553814327295098881", "entities": {"urls": [{"start": 150, "end": 173, "url": "https://t.co/ByZONxaMCs", "expanded_url": "https://twitter.com/romeerizwan/status/1553814327295098881/photo/1", "display_url": "pic.twitter.com/ByZONxaMCs", "media_key": "3_1553814317878886400"}], "mentions": [{"start": 66, "end": 77, "username": "WashUIMRes", "id": "1278033417096101888"}, {"start": 80, "end": 89, "username": "WUSTLmed", "id": "27779882"}, {"start": 95, "end": 109, "username": "TimeOutBoston", "id": "176449198"}, {"start": 118, "end": 132, "username": "MichaelJSlade", "id": "626650397"}, {"start": 135, "end": 148, "username": "DrHaleyEllis", "id": "764598685"}]}, "text": "Greatly enjoyed hanging out with some of my favorite people from \u2066@WashUIMRes\u2069 \u2066@WUSTLmed\u2069 at \u2066@TimeOutBoston\u2069 today \u2066@MichaelJSlade\u2069 \u2066@DrHaleyEllis\u2069 https://t.co/ByZONxaMCs", "lang": "en", "author_id": "15622046", "conversation_id": "1553814327295098881", "edit_history_tweet_ids": ["1553814327295098881"], "created_at": "2022-07-31T18:46:18.000Z"}, {"entities": {"annotations": [{"start": 75, "end": 78, "probability": 0.6614, "type": "Other", "normalized_text": "CD19"}], "urls": [{"start": 230, "end": 253, "url": "https://t.co/cT2YY9Jim8", "expanded_url": "https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2022007705/485992/Discovery-of-a-novel-genomic-alteration-that", "display_url": "ashpublications.org/bloodadvances/\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1585158469686276097/i9U6JvZM?format=png&name=orig", "width": 520, "height": 685}, {"url": "https://pbs.twimg.com/news_img/1585158469686276097/i9U6JvZM?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies", "description": "TO THE EDITOR:", "unwound_url": "https://ashpublications.org/bloodadvances/article/6/20/5634/485992/Discovery-of-a-novel-genomic-alteration-that"}]}, "id": "1552359706521395200", "text": "How small is too small? We identified that loss of a *single* codon in the CD19 locus led to antigen escape and CAR failure in a patient with ALL. Are there other small deletions that lead to escape? We've got to sequence more! \n\nhttps://t.co/cT2YY9Jim8", "lang": "en", "author_id": "1113150672894033921", "conversation_id": "1552359706521395200", "edit_history_tweet_ids": ["1552359706521395200"], "created_at": "2022-07-27T18:26:10.000Z"}, {"entities": {"annotations": [{"start": 37, "end": 45, "probability": 0.5878, "type": "Other", "normalized_text": "vitamin D"}], "urls": [{"start": 83, "end": 106, "url": "https://t.co/AUXMUq0xYu", "expanded_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2202106#.YuHdXrX5CDw.twitter", "display_url": "nejm.org/doi/full/10.10\u2026", "status": 200, "title": "Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults | NEJM", "description": "Original Article from The New England Journal of Medicine \u2014 Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults", "unwound_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2202106#.YuHdXrX5CDw.twitter"}]}, "id": "1552456804226981889", "text": "Another negative randomized trial of vitamin D supplementation in health adults? \n\nhttps://t.co/AUXMUq0xYu", "lang": "en", "author_id": "626650397", "conversation_id": "1552456804226981889", "edit_history_tweet_ids": ["1552456804226981889"], "created_at": "2022-07-28T00:52:00.000Z"}, {"referenced_tweets": [{"type": "replied_to", "id": "1551973068565688320"}], "id": "1551974678591246336", "text": "@ManniMD1 @AaronGoodman33 @RahulBanerjeeMD @rajshekharucms @HadidiSamer Thank you for the long explanation. Overstated outcome is pretty common in medical publications.", "lang": "en", "author_id": "2170278304", "conversation_id": "1551973006288621568", "edit_history_tweet_ids": ["1551974678591246336"], "created_at": "2022-07-26T16:56:12.000Z", "entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 10, "end": 25, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 26, "end": 42, "username": "RahulBanerjeeMD", "id": "26399236"}, {"start": 43, "end": 58, "username": "rajshekharucms", "id": "140966169"}, {"start": 59, "end": 71, "username": "HadidiSamer", "id": "774267564"}]}, "in_reply_to_user_id": "1269642863924609025"}, {"entities": {"annotations": [{"start": 13, "end": 17, "probability": 0.5177, "type": "Person", "normalized_text": "Woukd"}, {"start": 121, "end": 124, "probability": 0.4716, "type": "Organization", "normalized_text": "NCTN"}], "mentions": [{"start": 0, "end": 12, "username": "joshuaafein", "id": "89023598"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1551365116918202369"}], "id": "1551965779436138497", "text": "@joshuaafein Woukd encourage all Jr faculty and fellows interested in clinical/ translational research to participate in NCTN coop groups to work to inprove processes and develop new studies.", "lang": "en", "author_id": "985139345928736768", "conversation_id": "1551365116918202369", "edit_history_tweet_ids": ["1551965779436138497"], "created_at": "2022-07-26T16:20:50.000Z", "in_reply_to_user_id": "89023598"}, {"id": "1550212787334529029", "entities": {"urls": [{"start": 245, "end": 268, "url": "https://t.co/tGCiH13gfN", "expanded_url": "https://hemeoncfellowship.wustl.edu/", "display_url": "hemeoncfellowship.wustl.edu", "images": [{"url": "https://pbs.twimg.com/news_img/1550212833555750913/4IvFrIbp?format=jpg&name=orig", "width": 1920, "height": 964}, {"url": "https://pbs.twimg.com/news_img/1550212833555750913/4IvFrIbp?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Hematology-Oncology Fellowship Program", "description": "Information about the Hematology-Oncology Fellowship Program at Washington University", "unwound_url": "https://hemeoncfellowship.wustl.edu/"}]}, "text": "Applications are currently being accepted for our Fellowship program until 8/3/2022 at 11:59 CST. There are 8 Heme-Onc &amp; 1 Heme focused fellowship positions available. Please see the fellowship website for more information and how to apply! https://t.co/tGCiH13gfN", "lang": "en", "author_id": "1387867182609178624", "conversation_id": "1550212787334529029", "edit_history_tweet_ids": ["1550212787334529029"], "created_at": "2022-07-21T20:15:04.000Z"}, {"referenced_tweets": [{"type": "replied_to", "id": "1549806764786421762"}], "id": "1549960239969075201", "text": "@MichaelJSlade If you want an explanation, go to the source @jaltmanmd @Daver_Leukemia", "lang": "en", "author_id": "985139345928736768", "conversation_id": "1549806764786421762", "edit_history_tweet_ids": ["1549960239969075201"], "created_at": "2022-07-21T03:31:32.000Z", "entities": {"mentions": [{"start": 0, "end": 14, "username": "MichaelJSlade", "id": "626650397"}, {"start": 60, "end": 70, "username": "jaltmanmd", "id": "2228604786"}, {"start": 71, "end": 86, "username": "Daver_Leukemia", "id": "2920960866"}]}, "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 116, "end": 119, "probability": 0.5814, "type": "Other", "normalized_text": "MLFS"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1549806764786421762"}], "id": "1549806766959075328", "text": "I wouldn't fixate on this except that almost half of the \"modified composite complete response\" patients (75%) were MLFS only (36%). This is a tough population to treat/recruit. Getting to 39% CR + CRi isn't bad (albeit with a ton of cytopenias). Just a weird primary endpoint.", "lang": "en", "author_id": "626650397", "conversation_id": "1549806764786421762", "edit_history_tweet_ids": ["1549806766959075328"], "created_at": "2022-07-20T17:21:41.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 71, "end": 90, "probability": 0.5042, "type": "Other", "normalized_text": "morphologic leukemia"}, {"start": 104, "end": 107, "probability": 0.5295, "type": "Other", "normalized_text": "MLFS"}, {"start": 185, "end": 188, "probability": 0.5716, "type": "Other", "normalized_text": "MLFS"}, {"start": 209, "end": 212, "probability": 0.7057, "type": "Other", "normalized_text": "NEJM"}], "urls": [{"start": 253, "end": 276, "url": "https://t.co/QdUgLbC95x", "expanded_url": "https://ascopubs.org/doi/full/10.1200/JCO.22.00602?bid=186376274&cid=DM11069", "display_url": "ascopubs.org/doi/full/10.12\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1549806807383695361/WbNiRweH?format=png&name=orig", "width": 269, "height": 269}, {"url": "https://pbs.twimg.com/news_img/1549806807383695361/WbNiRweH?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia", "description": "PURPOSE The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy for relapsed/refractory FLT3-mutated (FLT3mut) acute myeloid leukemia (AML) but seldom reduces FLT3mut burden or induces sustained efficacy. Gilteritinib combines synergistically with the BCL-2 inhibitor venetoclax in preclinical models of FLT3mut AML. METHODS This phase Ib open-label, dose-escalation/dose-expansion study (ClinicalTrials.gov identifier: NCT03625505) enrolled patients with FLT3 wild-type and FLT3mut (escalation) or FLT3mut (expansion) relapsed/refractory AML. Patients received 400 mg oral venetoclax once daily and 80 mg or 120 mg oral gilteritinib once daily. The primary objectives were safety, identification of the recommended phase II dose, and the modified composite complete response (mCRc) rate (complete response [CR] + CR with incomplete blood count recovery + CR with incomplete platelet recovery + morphologic leukemia-free state) using ADMIRAL phase III\u2013defined response cri", "unwound_url": "https://ascopubs.org/doi/full/10.1200/JCO.22.00602?bid=186376274&cid=DM11069"}]}, "id": "1549806764786421762", "text": "What's going on with the response criteria in this trial? They include morphologic leukemia-free state (MLFS) in the composite endpoint and keep referencing the \"ADMIRAL criteria.\" But MLFS is not in the 2019 NEJM manuscript, supplement or protocol.  \n\nhttps://t.co/QdUgLbC95x", "lang": "en", "author_id": "626650397", "conversation_id": "1549806764786421762", "edit_history_tweet_ids": ["1549806764786421762"], "created_at": "2022-07-20T17:21:41.000Z"}, {"entities": {"annotations": [{"start": 24, "end": 37, "probability": 0.6482, "type": "Other", "normalized_text": "Timothy J. Ley"}, {"start": 89, "end": 108, "probability": 0.81, "type": "Other", "normalized_text": "Henry Stratton Medal"}], "urls": [{"start": 256, "end": 279, "url": "https://t.co/eyVexxYanR", "expanded_url": "http://ow.ly/abhb50JUhBE", "display_url": "ow.ly/abhb50JUhBE", "images": [{"url": "https://pbs.twimg.com/news_img/1549001464802050048/4JA3JFDR?format=jpg&name=orig", "width": 220, "height": 238}, {"url": "https://pbs.twimg.com/news_img/1549001464802050048/4JA3JFDR?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Ley honored for groundbreaking leukemia research - Siteman Cancer Center", "description": "\u00a0 Timothy J. Ley, MD, the Lewis T. and Rosalind B. Apple Professor of Medicine, has been honored by the American Society of Hematology with the Henry - Siteman Cancer Center", "unwound_url": "https://siteman.wustl.edu/ley-honored-for-groundbreaking-leukemia-research/?utm_source=twitter&utm_medium=Organic&utm_campaign=news_staff&utm_id=leukemia"}], "mentions": [{"start": 1, "end": 10, "username": "WUSTLmed", "id": "27779882"}, {"start": 64, "end": 79, "username": "ASH_hematology", "id": "84072624"}]}, "id": "1549001422326403072", "text": ".@WUSTLmed hematologist Timothy J. Ley, MD, has been honored by @ASH_hematology with the Henry Stratton Medal. The award recognizes the outstanding contributions of one scientist &amp; one researcher to the field of hematology.\n\nCongratulations, Dr. Ley!: https://t.co/eyVexxYanR", "lang": "en", "author_id": "89517086", "conversation_id": "1549001422326403072", "edit_history_tweet_ids": ["1549001422326403072"], "created_at": "2022-07-18T12:01:32.000Z"}, {"entities": {"annotations": [{"start": 63, "end": 70, "probability": 0.6062, "type": "Other", "normalized_text": "De Togni"}, {"start": 138, "end": 140, "probability": 0.5042, "type": "Other", "normalized_text": "CRS"}, {"start": 153, "end": 153, "probability": 0.4847, "type": "Other", "normalized_text": "-"}], "urls": [{"start": 231, "end": 254, "url": "https://t.co/q9IrVDEVrw", "expanded_url": "https://tinyurl.com/mrxv9e6p", "display_url": "tinyurl.com/mrxv9e6p", "images": [{"url": "https://pbs.twimg.com/news_img/1549039711414816768/b6FXp9_0?format=jpg&name=orig", "width": 555, "height": 723}, {"url": "https://pbs.twimg.com/news_img/1549039711414816768/b6FXp9_0?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "The impact of tocilizumab treatment for cytokine release syndrome on the incidence of early blood stream infections after peripheral blood haploidentical hematopoietic cell transplantation", "description": "Cytokine release syndrome (CRS) is a potentially fatal systemic inflammatory response that can occur in patients undergoing peripheral blood haploidentical hematopoietic cell transplantation (haplo...", "unwound_url": "https://www.tandfonline.com/doi/full/10.1080/10428194.2022.2100367"}], "mentions": [{"start": 36, "end": 47, "username": "WashUIMRes", "id": "1278033417096101888"}, {"start": 173, "end": 182, "username": "ramziabb", "id": "889186404"}, {"start": 216, "end": 228, "username": "romeerizwan", "id": "15622046"}]}, "id": "1549039706465521664", "text": "Strong work by one of our fantastic @WashUIMRes residents, Dr. De Togni, looking at the impact on infection risk of early tocilizumab for CRS after haplo-HCT. \n\nMentored by @ramziabb, continuing work he started with @romeerizwan.\n\nhttps://t.co/q9IrVDEVrw", "lang": "en", "author_id": "626650397", "conversation_id": "1549039706465521664", "edit_history_tweet_ids": ["1549039706465521664"], "created_at": "2022-07-18T14:33:40.000Z"}, {"referenced_tweets": [{"type": "quoted", "id": "1544700457515352066"}], "id": "1544719941873590272", "entities": {"urls": [{"start": 124, "end": 147, "url": "https://t.co/3YshtgUpgQ", "expanded_url": "https://twitter.com/DamonRunyon/status/1544700457515352066", "display_url": "twitter.com/DamonRunyon/st\u2026"}], "mentions": [{"start": 35, "end": 44, "username": "WUSTLmed", "id": "27779882"}, {"start": 98, "end": 107, "username": "WashUDPS", "id": "1276507179575541761"}, {"start": 108, "end": 123, "username": "WUDeptMedicine", "id": "1105452868771946497"}]}, "text": "Congrats to all awardees including @WUSTLmed rising star physician-scientist @NathanSinghLab1! \ud83e\udd29\ud83d\udcaa @WashUDPS @WUDeptMedicine https://t.co/3YshtgUpgQ", "lang": "en", "author_id": "2930528191", "conversation_id": "1544719941873590272", "edit_history_tweet_ids": ["1544719941873590272"], "created_at": "2022-07-06T16:28:28.000Z"}, {"entities": {"annotations": [{"start": 63, "end": 72, "probability": 0.9069, "type": "Other", "normalized_text": "MedTwitter"}, {"start": 75, "end": 85, "probability": 0.7406, "type": "Other", "normalized_text": "Nephtwitter"}], "hashtags": [{"start": 62, "end": 73, "tag": "MedTwitter"}, {"start": 74, "end": 86, "tag": "Nephtwitter"}], "urls": [{"start": 87, "end": 110, "url": "https://t.co/BjFZMy8FxZ", "expanded_url": "https://twitter.com/NicoGagelmann/status/1544336266216472580/photo/1", "display_url": "pic.twitter.com/BjFZMy8FxZ", "media_key": "3_1544336262416502784"}]}, "id": "1544336266216472580", "text": "Who measures cystatin c in clinical practice, when and why? \n\n#MedTwitter #Nephtwitter https://t.co/BjFZMy8FxZ", "lang": "en", "author_id": "1054759355512438786", "conversation_id": "1544336266216472580", "edit_history_tweet_ids": ["1544336266216472580"], "created_at": "2022-07-05T15:03:52.000Z"}, {"id": "1542899870503211016", "text": "scare a scientist with 6 words", "lang": "en", "author_id": "1477363087737032708", "conversation_id": "1542899870503211016", "edit_history_tweet_ids": ["1542899870503211016"], "created_at": "2022-07-01T15:56:09.000Z"}, {"entities": {"annotations": [{"start": 97, "end": 99, "probability": 0.524, "type": "Other", "normalized_text": "MRD"}, {"start": 108, "end": 110, "probability": 0.6021, "type": "Organization", "normalized_text": "PCR"}]}, "id": "1541889275448508416", "text": "Young man with Ph+ ALL treated with imatinib plus chemotherpy, now 6 months in maintenance still MRD neg by PCR and flow\n\nOnly has access to imatinib, has matched sibling donor, he wants alloHSCT you recommend:", "lang": "en", "author_id": "1039939970415218688", "conversation_id": "1541889275448508416", "edit_history_tweet_ids": ["1541889275448508416"], "created_at": "2022-06-28T21:00:24.000Z"}, {"referenced_tweets": [{"type": "replied_to", "id": "1540775393132572674"}], "id": "1540806938237276161", "text": "@CalculatingMind That was how it was a long time ago. Puts psychiatrists in an interesting role bc like\u2026what does certifying mean?", "lang": "en", "author_id": "785968989092446209", "conversation_id": "1540769555924062208", "edit_history_tweet_ids": ["1540806938237276161"], "created_at": "2022-06-25T21:19:35.000Z", "entities": {"mentions": [{"start": 0, "end": 16, "username": "CalculatingMind", "id": "4821114131"}]}, "in_reply_to_user_id": "4821114131"}, {"entities": {"annotations": [{"start": 225, "end": 226, "probability": 0.4745, "type": "Other", "normalized_text": "MM"}], "mentions": [{"start": 0, "end": 10, "username": "bdermanmd", "id": "872983600416862208"}, {"start": 11, "end": 25, "username": "docbraunstein", "id": "2333504019"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1540704190107996160"}], "id": "1540708075291627520", "text": "@bdermanmd @docbraunstein Are there already abbreviations / terms that capture the distinction between a biochemical progression and a more sort of clinical/bodily progression? (And I'm not a doctor; would this apply only in MM, or in other cancers also?)", "lang": "en", "author_id": "1302975798304014336", "conversation_id": "1540701933425504256", "edit_history_tweet_ids": ["1540708075291627520"], "created_at": "2022-06-25T14:46:44.000Z", "in_reply_to_user_id": "872983600416862208"}, {"referenced_tweets": [{"type": "replied_to", "id": "1540427622093623296"}], "id": "1540433736050827264", "text": "@MichaelJSlade Prettt scary to see a hematologist who is supposed to be an expert in calculating risk vs benefit get swept up in political rhetoric.", "lang": "en", "author_id": "1508704605173133315", "conversation_id": "1540427622093623296", "edit_history_tweet_ids": ["1540433736050827264"], "created_at": "2022-06-24T20:36:37.000Z", "entities": {"mentions": [{"start": 0, "end": 14, "username": "MichaelJSlade", "id": "626650397"}]}, "in_reply_to_user_id": "626650397"}, {"referenced_tweets": [{"type": "replied_to", "id": "1539729112809570306"}], "id": "1539729114051084288", "text": "Would stratifying the models\nby trial be enough to compensate for this effect?", "lang": "en", "author_id": "626650397", "conversation_id": "1539729112809570306", "edit_history_tweet_ids": ["1539729114051084288"], "created_at": "2022-06-22T21:56:42.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 107, "end": 110, "probability": 0.3683, "type": "Organization", "normalized_text": "NDMM"}], "urls": [{"start": 242, "end": 265, "url": "https://t.co/zYVgl8cEGo", "expanded_url": "https://tinyurl.com/5ct4fdp2", "display_url": "tinyurl.com/5ct4fdp2", "images": [{"url": "https://pbs.twimg.com/news_img/1539729119717597191/VXAMxF_1?format=png&name=orig", "width": 520, "height": 685}, {"url": "https://pbs.twimg.com/news_img/1539729119717597191/VXAMxF_1?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials", "description": "Key Points. Black and Hispanic patients are underrepresented in global MM clinical trials.Black patients enrolled in the United States had better survival outco", "unwound_url": "https://ashpublications.org/bloodadvances/article/6/6/1684/483828/Analysis-of-racial-and-ethnic-disparities-in"}], "mentions": [{"start": 34, "end": 48, "username": "BloodAdvances", "id": "732570175162179585"}]}, "id": "1539729112809570306", "text": "Reading this (important) paper in @BloodAdvances and I can\u2019t figure out if they adjusted for enrollment in NDMM vs R/R MM trials. 92% of AA vs 68% of white pts were enrolled in R/R trials and likely significant confounding if not adjusted. \n\nhttps://t.co/zYVgl8cEGo", "lang": "en", "author_id": "626650397", "conversation_id": "1539729112809570306", "edit_history_tweet_ids": ["1539729112809570306"], "created_at": "2022-06-22T21:56:41.000Z"}, {"entities": {"annotations": [{"start": 17, "end": 26, "probability": 0.8028, "type": "Person", "normalized_text": "Miriam Kim"}, {"start": 120, "end": 124, "probability": 0.7054, "type": "Other", "normalized_text": "NT-I7"}, {"start": 154, "end": 158, "probability": 0.5246, "type": "Other", "normalized_text": "leusm"}], "hashtags": [{"start": 153, "end": 159, "tag": "leusm"}, {"start": 160, "end": 166, "tag": "lymsm"}, {"start": 167, "end": 174, "tag": "cartsm"}], "urls": [{"start": 191, "end": 214, "url": "https://t.co/UgrbAbvKnJ", "expanded_url": "https://www.nature.com/articles/s41467-022-30860-0", "display_url": "nature.com/articles/s4146\u2026", "status": 200, "unwound_url": "https://www.nature.com/articles/s41467-022-30860-0?error=cookies_not_supported&code=a3ed0800-64aa-4816-81fd-2149a9aad2de"}], "mentions": [{"start": 32, "end": 44, "username": "DiPersioLab", "id": "1349142172415762433"}, {"start": 48, "end": 60, "username": "NatureComms", "id": "206255645"}, {"start": 176, "end": 190, "username": "SitemanCenter", "id": "89517086"}]}, "id": "1539563616290197506", "text": "New paper out by Miriam Kim and @DiPersioLab in @NatureComms showing how to enhance CART expansion and persistence with NT-I7. Clinical trial is ongoing #leusm #lymsm #cartsm  @SitemanCenter https://t.co/UgrbAbvKnJ", "lang": "en", "author_id": "985139345928736768", "conversation_id": "1539563616290197506", "edit_history_tweet_ids": ["1539563616290197506"], "created_at": "2022-06-22T10:59:04.000Z"}, {"entities": {"annotations": [{"start": 7, "end": 9, "probability": 0.6274, "type": "Other", "normalized_text": "KRd"}, {"start": 28, "end": 30, "probability": 0.6733, "type": "Other", "normalized_text": "MRD"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1538403462836256768"}], "id": "1538403464275009538", "text": "In the KRd arm 47% achieved MRD negative compared to 29% in the R arm after 6 cycles! They missed adding a fixed duration", "lang": "en", "author_id": "1026947037080772610", "conversation_id": "1538403462836256768", "edit_history_tweet_ids": ["1538403464275009538"], "created_at": "2022-06-19T06:09:02.000Z", "in_reply_to_user_id": "1026947037080772610"}, {"referenced_tweets": [{"type": "replied_to", "id": "1538162492022484992"}], "id": "1538186242730340352", "entities": {"urls": [{"start": 16, "end": 39, "url": "https://t.co/CmXjBpcB2L", "expanded_url": "https://twitter.com/Sthanu5/status/1538186242730340352/photo/1", "display_url": "pic.twitter.com/CmXjBpcB2L", "media_key": "3_1538186226133442561"}], "mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "text": "@AaronGoodman33 https://t.co/CmXjBpcB2L", "lang": "qme", "author_id": "821765042051784705", "conversation_id": "1538162492022484992", "edit_history_tweet_ids": ["1538186242730340352"], "created_at": "2022-06-18T15:45:53.000Z", "in_reply_to_user_id": "854692626015993857"}, {"referenced_tweets": [{"type": "replied_to", "id": "1537808434741096450"}], "id": "1537955855470977024", "text": "@MichaelJSlade @CyclingDoctor @dgermain21 @mpndoc @VPrasadMDMPH @NTrikalinos @RPachynski I kind of think that if you want to publish in the journal, you play by their rules. It also depends on what you think of the comments because it sounds like you disagree with some of them.", "lang": "en", "author_id": "985139345928736768", "conversation_id": "1537806644863807488", "edit_history_tweet_ids": ["1537955855470977024"], "created_at": "2022-06-18T00:30:24.000Z", "entities": {"mentions": [{"start": 0, "end": 14, "username": "MichaelJSlade", "id": "626650397"}, {"start": 15, "end": 29, "username": "CyclingDoctor", "id": "23036480"}, {"start": 30, "end": 41, "username": "dgermain21", "id": "18821994"}, {"start": 42, "end": 49, "username": "mpndoc", "id": "2930528191"}, {"start": 50, "end": 63, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 64, "end": 76, "username": "NTrikalinos", "id": "1242826524010651653"}, {"start": 77, "end": 88, "username": "RPachynski", "id": "1179604816198275072"}]}, "in_reply_to_user_id": "626650397"}, {"id": "1537689553821212680", "text": "Sitting in the plane on the tarmac is one of the most boring things to do", "lang": "en", "author_id": "964268621655695360", "conversation_id": "1537689553821212680", "edit_history_tweet_ids": ["1537689553821212680"], "created_at": "2022-06-17T06:52:13.000Z"}, {"entities": {"annotations": [{"start": 63, "end": 65, "probability": 0.4055, "type": "Organization", "normalized_text": "ITT"}]}, "referenced_tweets": [{"type": "replied_to", "id": "1537812977411248128"}], "id": "1537812980082954245", "text": "This is because in real life, folks often follow protocols. An ITT analysis is MUCH more generalizable to real-life scenarios.\n\nBut sometimes clinical trial can be tough to follow. In this case, many investigators would choose to continue longer abx even if on short abx arm!", "lang": "en", "author_id": "1269642863924609025", "conversation_id": "1537812935845629955", "edit_history_tweet_ids": ["1537812980082954245"], "created_at": "2022-06-17T15:02:40.000Z", "in_reply_to_user_id": "1269642863924609025"}, {"referenced_tweets": [{"type": "replied_to", "id": "1537806644863807488"}], "id": "1537808433302355969", "text": "And I don't mean \"You have a typo\", \"Please add data on X\" or \"You didn't acknowledge this limitation\" type comments. I'm talking \"Please re-focus discussion on Y\" or \"Cite and discuss specific paper Z\"", "lang": "en", "author_id": "626650397", "conversation_id": "1537806644863807488", "edit_history_tweet_ids": ["1537808433302355969"], "created_at": "2022-06-17T14:44:36.000Z", "in_reply_to_user_id": "626650397"}, {"entities": {"annotations": [{"start": 1, "end": 10, "probability": 0.8841, "type": "Other", "normalized_text": "MedTwitter"}], "hashtags": [{"start": 0, "end": 11, "tag": "MedTwitter"}]}, "id": "1537806644863807488", "text": "#MedTwitter, please advise\n\nScenario: \n\nYour paper is rejected (without revision) from journal #1. Journal #2 requires you submit prior reviewer comments if considered for publication elsewhere. \n\nQuestion:\n\nAre you obligated to address all the reviewer concerns from journal #1?", "lang": "en", "author_id": "626650397", "conversation_id": "1537806644863807488", "edit_history_tweet_ids": ["1537806644863807488"], "created_at": "2022-06-17T14:37:29.000Z"}, {"entities": {"annotations": [{"start": 120, "end": 124, "probability": 0.832, "type": "Other", "normalized_text": "Waqar"}, {"start": 130, "end": 133, "probability": 0.6152, "type": "Other", "normalized_text": "Saif"}, {"start": 163, "end": 169, "probability": 0.8023, "type": "Other", "normalized_text": "Heather"}, {"start": 175, "end": 180, "probability": 0.8071, "type": "Other", "normalized_text": "Cheryl"}], "urls": [{"start": 246, "end": 269, "url": "https://t.co/9wfJEkYA0N", "expanded_url": "https://twitter.com/mpndoc/status/1537646806535897090/photo/1", "display_url": "pic.twitter.com/9wfJEkYA0N", "media_key": "3_1537646801498644483"}], "mentions": [{"start": 187, "end": 197, "username": "WashUHeme", "id": "1387867182609178624"}, {"start": 198, "end": 213, "username": "WUDeptMedicine", "id": "1105452868771946497"}, {"start": 214, "end": 224, "username": "WashUFWIM", "id": "1138987375516893184"}, {"start": 225, "end": 234, "username": "WashUDPS", "id": "1276507179575541761"}, {"start": 235, "end": 245, "username": "awn_wustl", "id": "1186127018926186496"}]}, "id": "1537646806535897090", "text": "Celebrating our graduating fellows tonight gotta give a shoutout for the tireless efforts of our Program Directors Drs. Waqar and Saif and Fellowship Coordinators Heather and Cheryl! \ud83e\udd29\ud83d\udc4f\ud83d\udcaa\ud83c\udffc@WashUHeme @WUDeptMedicine @WashUFWIM @WashUDPS @awn_wustl https://t.co/9wfJEkYA0N", "lang": "en", "author_id": "2930528191", "conversation_id": "1537646806535897090", "edit_history_tweet_ids": ["1537646806535897090"], "created_at": "2022-06-17T04:02:21.000Z"}]}, "errors": [{"value": "1550179700353507330", "detail": "Could not find tweet with referenced_tweets.id: [1550179700353507330].", "title": "Not Found Error", "resource_type": "tweet", "parameter": "referenced_tweets.id", "resource_id": "1550179700353507330", "type": "https://api.twitter.com/2/problems/resource-not-found"}], "meta": {"next_token": "7140dibdnow9c7btw421tf9cm1hz57g7oa0jg2kthxz5c", "result_count": 100, "newest_id": "1601016176108523520", "oldest_id": "1537805434651803650"}, "neighbors": ["18821994", "985139345928736768", "23036480", "27779882", "854692626015993857", "1269642863924609025", "1198731683199098881"]}